[{"article": "That view is shared by Deborah Giaschi, a professor of ophthalmology and visual sciences at the University of British Columbia in Vancouver who has conducted MRI studies of the brains of people with dyslexia. \"There's really no scientific basis\" for ChromaGen lenses, she says. In her opinion, the claim that the lenses slow down visual processing doesn't make sense. Even if the lenses had that effect, she doesn't see how that would help anyone read.", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering.\nIn fact, the story explained that dyslexia \u201cis a complex and controversial condition\u201d and that one optometrist said \u201cthere are different types of dyslexia, and only people who have trouble with visual distortions while reading are likely to benefit.\u201d", "answer": 1}, {"article": "Of these, 40% (574) were nulliparous women, 870 (60%) women completed 3 years of the study, 707 (49%) elected to enroll in an extension phase up to a total of 5 years, and 550 (38%) completed 5 years of use.\nKyleena is available by prescription only.\nKyleena is a trademark of Bayer.\nOnly you and your healthcare provider can decide if Kyleena is right for you.\n\u2022 Ovarian cysts may occur but usually disappear.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "Fasting blood samples were taken at the start of the trial and then at intervals of one, three, and six weeks.\nThe researchers signed up 20 people and put them at random into two groups, one receiving a placebo and the other a supplement containing 40 milligrams of resveratrol.\nStudy author Husam Ghanim, PhD, of the University of Buffalo says the popular plant extract has been shown to prolong life and reduce the rate of aging in roundworms, fruit flies, and yeast, apparently because resveratrol affects a gene associated with longevity.\nResults showed that resveratrol suppressed the generation of \u201cfree radicals\u201d -- unstable molecules known to cause oxidative stress and release pro-inflammatory substances into the blood, resulting in damage to the blood vessel lining.\nPeople taking resveratrol also showed suppression of the inflammatory protein tumor necrosis factor, or TNF, and other compounds that increase blood vessel inflammation and interfere with insulin action, causing insulin resistance and the risk of developing diabetes.\n", "question": "Does the story commit disease-mongering?", "explanation": "Intermediate endpoints or surrogate markers \u2013 such as blood levels of \"pro-inflammatory markers\" do NOT equate to \"may slow aging\" as the headline suggests.\u00a0 Yet the story made the leap to say that \"resveratrol reduces inflammation in humans that could lead to heart disease, stroke, and type 2 diabetes.\"\nBut let\u2019s drop back to a bigger picture:\u00a0 Shouldn\u2019t we introduce at least a line in the story about whether aging is a disease requiring treatment? This is the way the story was framed \u2013 appearing in WebMD\u2019s \"Healthy Aging Health Center\" with four mentions of aging in the short story. ", "answer": 0}, {"article": "\u2022 Shepstone et al (2017).\nThe research, involving more than 12,000 older women and carried out in collaboration between the universities of Birmingham, East Anglia, Bristol, Leicester, York and Sheffield, found that screening through GP practices allowed patients to be targeted for treatment.\n\u2022 The International Osteoporosis Foundation (IOF) is the world's largest nongovernmental organization dedicated to the prevention, diagnosis and treatment of osteoporosis and related musculoskeletal diseases.\nIt assists primary health-care providers to better target people in need of interventions to reduce fracture risk, thus improving the allocation of health-care resources towards patients most likely to benefit from treatment.\n\u2022 FRAX\u00ae is a simple calculation tool that integrates clinical information in a quantitative manner to predict a 10-year probability of major osteoporotic fracture for both women and men in different countries.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release takes a balanced approach to the severity of the health issue under study. There is no disease mongering. Hip fractures are common and are associated with poor outcomes \u2014 disability, loss of independence, and death.", "answer": 1}, {"article": "Risk reduction [was] probably in the range of 80 to 95 percent,\" said researcher Timothy Rebbeck, an epidemiologist at the University of Pennsylvania.\nA new study in the Journal of the American Medical Association shows the clearest evidence yet that women carrying the BRCA1 and BRCA2 genes should consider preventive surgery because they are at a very high risk for breast and ovarian cancers.\nThe study findings are extremely reassuring to Rebbeck -- no breast cancer diagnoses among women who had double mastectomies after three years of follow-up.\n\"My mother left me when I was 26, and it was extremely painful and traumatic for my entire life,\" she says.\nIt confirms what smaller studies have suggested in the past: Women who have a family history of breast cancer can greatly reduce their chances of getting the disease by having a double mastectomy.\n", "question": "Does the story commit disease-mongering?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nWhile the story notes that this study looked at women with BRCA1 and BRCA2 gene mutations, it then went on to claim that \u201cWomen who have a family history of breast cancer\u201d can reduce their chances of getting cancer if they have surgery. In fact, most women with a family history of breast cancer do not have the specific genetic mutations studied by these researchers. The story is likely to make readers believe the findings are relevant to a far larger number of women than is actually the case.", "answer": 0}, {"article": "A capsule of Probiotic Immunity from New Chapter Inc., based in Brattleboro, Vt., contains 1 billion each of 10 different organisms, including Streptococcus salivarius subsp. thermophilus and Lactobacillus acidophilus, two species of bacteria often found in yogurt. Other ingredients include herbs such as cumin, ginger and spinach. Users are instructed to take two capsules each day, preferably one in the morning and one in the evening, on an empty stomach. You can buy a bottle of 90 capsules for about $20 at many health food stores.", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering.", "answer": 1}, {"article": "Media Advisory: To contact corresponding author Susan L. McElroy, M.D., call Jennifer Pierson at 513-536-0316 or email jennifer.pierson@lindnercenter.org\n\"In the primary analysis of this study of adults with moderate to severe BED, lisdexamfetamine dimesylate treatment with 50 and 70 mg/d, but not 30 mg/d, demonstrated a significant decrease (compared with placebo) in weekly BE days per week at week 11.\nThe one-week BE episode response status was improved in the 50- and 70-mg/d treatment groups, and a greater proportion of participants achieved four-week cessation of BE episodes and global improvement of symptom severity with all lisdexamfetamine dosages.\nAt some doses, the medication lisdexamfetamine dimesylate, a drug approved to treat attention-deficit/hyperactivity disorder, was effective compared with placebo in decreasing binge-eating (BE) days in patients with binge-eating disorder (BED), a public health problem associated symptoms of mental illness and obesity and for which there are no approved medications, according to a study published online by JAMA Psychiatry.\nResults also indicate the percentage of patients who achieved four-week BE cessation was lower with the placebo group (21.3 percent) compared with the 50-mg/d (42.2 percent) and 70-mg/d (50 percent) treatment groups.\n", "question": "Does the news release commit disease-mongering?", "explanation": "Although the news release is free of emotionally wrenching\u00a0words or phrases, binge-eating disorder\u00a0itself would be considered by some to be an example of disease mongering. It is essentially a problem of overeating, differentiated from other psychiatric eating disorders (anorexia and bulimia) by the lack of purging or fasting to compensate for the overeating. It was originally codified as a disorder\u00a0worthy of further study in DSM-IV, by a work-group that was heavily involved with industry. DSM-V added it as an official diagnosis. The eating disorders work-group had become less conflicted, but still 50% of members reported COIs.\nGiven the nation\u2019s obsession with weight and overeating, one can see how many people will be convinced they have this disorder. In the buildup to the drug\u2019s expanded approval, drugmaker Shire played an active role marketing awareness of binge-eating disorder, as The New York Times reported.", "answer": 1}, {"article": "And the chunky monkeys?\n\"If the promise holds true, I think this has the chance to change healthcare,\" Dr. Christoph Westphal tells\n\nDr. Westphal says we all may soon be taking a drug that just might beat the clock, a simple pill that could delay the inevitable.\nMost researchers agreed that there was something in the wine that offered protection, and a few years later, even the highly cautious federal dietary guidelines say that moderate consumption of red wine can be beneficial.\n\"Our goal is to prevent and forestall many of the diseases that strike us as we reach 50, 60, and 70.\n\"When I Googled this resveratrol, I was shocked to find that red wine was the top hit,\" Sinclair remembers.\n", "question": "Does the story commit disease-mongering?", "explanation": "The intro to the story suggests that \"we all may soon be taking a pill that could give us an extra decade or two of healthy old age.\"\u00a0 We understand that they want to keep us tuned in with flashy intros.\u00a0 But there are many people who do not embrace the \"pill for every ill\" mentality and, indeed, will predictably NOT be among the predicted universe of people who would pop such a pill even if it did pan out \u2013 which is a long way away to say the very least \u2013 not \"soon\" as promised. \nThe story also stated that \"The pill \u2026 could prevent the diseases of aging, like Alzheimer\u2019s, diabetes, heart disease, even cancer.\"\u00a0 Perhaps.\u00a0 It may also be shown to be unable to do so.\u00a0 This is wild hyperbole that just isn\u2019t necessary or warranted.\u00a0 Stick to what\u2019s known now and let the future unfold as it does.\u00a0 ", "answer": 0}, {"article": "SUNDAY, March 6, 2011 (HealthDay News) -- A simple blood test may one day offer a safe way to detect Down syndrome during pregnancy, researchers say.\nOlder mothers are more likely to give birth to Down syndrome babies.\n\"The cost is much lower than the invasive procedures,\" he said.\nHeart defects and other health problems are also common, according to the March of Dimes.\n\"We estimate we can introduce this to clinical practice in a couple of years.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering.", "answer": 1}, {"article": "Currently, guidelines reserve breast MRI screening for women who have a strong family history or other specific breast cancer risk factors.\nCollaborating with Dr. Kuhl were Kevin Strobel, M.D., Heribert Bieling, M.Sc., Claudia Leutner, M.D., Hans H. Schild, M.D., Ph.D., and Simone Schrading, M.D., Ph.D.\n\nRadiology is edited by Herbert Y. Kressel, M.D., Harvard Medical School, Boston, Mass., and owned and published by the Radiological Society of North America, Inc. (http://radiology. )\nAccording to Dr. Kuhl, interval cancers exhibit an adverse biologic profile and are the main driver of breast cancer mortality.\n\"The faster a cancer grows and the better it is in seeding metastases, the better will it be picked up early by MRI,\" Dr. Kuhl said.\nAccording to Dr. Kuhl, the results suggest that MRI can serve as a useful supplemental screening tool for women at average risk, especially those with dense mammographic tissue, and that MRI is superior to supplemental ultrasound for this purpose.\n", "question": "Does the news release commit disease-mongering?", "explanation": "Breast cancer\u2019s prevalence in cancer-related deaths in women\u00a0was highlighted but not overstated.\nBut we aren\u2019t told whether the 20 cases of non-invasive cancer identified were ductal carcinoma in situ (DCIS). There\u2019s wide debate on whether the presence of these types of abnormal cells should even be referred to as cancer. The lack of clarity on the types of cancer identified and the difference between them earns a Not Satisfactory rating. ", "answer": 0}, {"article": "MONDAY, Oct. 15, 2012 (HealthDay News) -- A prescription medication originally developed to treat epilepsy may help obese adults shed weight when combined with routine nutritional counseling, researchers say.\nAll study participants followed their treatment plan for one year.\n\"There's no medicine that is a panacea for obesity,\" cautioned Gadde.\nPsychological factors or lifestyle factors may play a role, he said.\nNone had diabetes.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering.", "answer": 1}, {"article": "But the F.D.A.\nDr. Min said in an e-mail message that foam sclerotherapy was \u201cvery safe,\u201d but that \u201cit is associated with higher risks than liquid sclerotherapy.\u201d Foam injections have been blamed as the cause of blood clots in leg veins, he wrote, adding that one known stroke \u201cmay have been caused by foam sclerotherapy.\u201d\n\nBut foam sclerotherapy has been a big relief for some patients.\nThat said, polidocanol was the \u201csecond most commonly used sclerosing agent\u201d because, he said, \u201cmost physicians want to give their patients the best available treatment.\u201d\n\nF.D.A.\nYet, he said both are \u201cvery safe and effective, and a heck of a lot better than surgery.\u201d (It entailed ripping out the groin-to-ankle vein with a wire via an incision.)\nBy contrast, he said by e-mail, Asclera \u201cis very safe for skin.\u201d\n\nAn injector\u2019s experience matters, because if the injection misses the vein, (or open sores) can occur.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story claims that\u00a0doctors\u00a0believe\u00a0everyone with varicose veins\u00a0should seek out medical care. Excerpt: \nReally?\u00a0 How many doctors?\u00a0 Who are these doctors?\u00a0 Are they doctors who stand to gain from treating this condition? This is a terribly misleading generalization. While it is true that a minority of patients are at risk of more serious medical problems related to their varicose veins, the vast majority of people have nothing to fear and don\u2019t need to see a doctor. The article should have\u00a0emphasized the benign nature of most varicose veins and identified the uncommon circumstances\u00a0under which people should seek out medical attention for potential health risks.\u00a0\u00a0\u00a0", "answer": 0}, {"article": "Kite Pharma is racing to get the first FDA approval of an experimental gene therapy to fight cancer.\n\nAn experimental gene therapy that turns a patient\u2019s own blood cells into cancer killers worked in a major study, with more than one-third of very sick lymphoma patients showing no sign of disease six months after a single treatment, its maker said Tuesday.\n\nIn all, 82 percent of patients had their cancer shrink at least by half at some point in the study.", "question": "Does the story commit disease-mongering?", "explanation": "The story did not disease monger. These lymphomas are serious and aggressive forms of blood cancer.", "answer": 1}, {"article": "\"A majority of our patients with osteoarthritis of the knee saw significant pain reduction, not only just a few days after the procedure, but a month after as well, making this an accessible treatment for patients looking to improve their quality of life without surgery,\" said Sandeep Bagla, M.D., director of interventional radiology at the Vascular Institute of Virginia and lead author of the study.\nThis study builds on the growing international research around GAE and osteoarthritis.\nAs an outpatient treatment, GAE does not require open surgery or physical therapy, and takes 45-90 minutes to perform.\nBut GAE provides another option for patients struggling with pain and may even allow patients to avoid the painful recovery of knee surgery and the need for the kind of opioid pain medications associated with the dangerous epidemic in the United States.\"\nA second randomized controlled clinical trial began in February 2018 and will provide further data on what types of patients are the best candidates for this treatment and how it could move toward clinical practice.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t engage in disease mongering.", "answer": 1}, {"article": "Dr. Schumer said those grim statistics underscore the need for early detection, \u201cWe hope that breath analysis will allow us to diagnose patients with primary or recurrent lung cancer long before they suffer from symptoms, when we have more options for treating them, giving them the best chance for cure.\u201d\n\nCurrently, lung cancer patients are followed after surgery with chest computed tomography (CT) scans, which can be inconvenient, expensive, and expose the patient to radiation.\nHow the Breath Test WorksThe process of breath analysis is relatively simple.\n\u201cThe technology is pretty robust.\nBreath collection can be performed in the doctor\u2019s office.\n\u201cThis study confirms that the technology is accurate.\u201d\n\nLung cancer is the leading cause of cancer death.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There\u2019s no disease-mongering here.", "answer": 1}, {"article": "Chantix costs roughly $3 per pill.\n\"We are not currently performing any studies with Chantix, although other groups are actively pursuing this line of research with a view to developing Chantix as an aid to people wanting to quit or cut down their drinking,\" Childs said.\nExactly how this drug curbs drinking is not fully understood, but its use may increase blood pressure, heart rate and feelings of sadness and nausea, thereby blunting the pleasurable effects of alcohol, the researchers said.\n\"Chantix increased the unpleasant effects of alcohol, for example feeling drowsy and irritable, [and] participants also reported that they didn't like the alcohol effects as much,\" Childs said.\nIn July 2009, the U.S. Food and Drug Administration mandated that Chantix carry a \"black box\" warning about the potential risks of depression and suicidal thoughts.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story notes that it \u201cremains to be seen\u201d whether Chantix might ever be recommended to help problem drinkers. However, the overall tone is that the drug could be useful, a message which may encourage people to try using the drug even though this test does not provide evidence that it works to curb alcohol consumption.\nMore important is this point: The source research study excluded alcoholics.\u00a0 Because the news article refers to the effect of Chantix on \u201cproblem drinkers\u201d without defining what that means, and includes\u00a0speculation that there might be a \u201cniche\u201d for this drug for\u00a0those with \u201calcohol-dependence issues,\u201d \u00a0the reader would be expected to think this article might apply to alcoholics.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Acupuncture may help relieve chronic back, joint and shoulder pain, according to a new review of the evidence - but some of its benefit is likely due to the \u201cplacebo effect,\u201d researchers concluded.\n\u201cI am a biased clinician,\u201d Park told Reuters Health.\n\u201cThis provides evidence that they would be justified in considering\u2026 acupuncture,\u201d he told Reuters Health.\nA typical acupuncture session runs for about $100 and is often not covered by health insurance.\nIn those cases, he said, acupuncture is very safe - and the main downsides are costs and the inconvenience of getting to a clinic.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease-mongering here.", "answer": 1}, {"article": "LONDON -- AstraZeneca PLC said Monday its experimental heart pill Brilinta was more effective at preventing heart attacks and strokes in a large clinical trial than the blockbuster pill Plavix, boosting commercial prospects for the U.K. drug maker's still unmarketed treatment.\n\nPlavix, which is marketed by Sanofi-Aventis SA and Bristol-Myers Squibb Co., was the second-biggest-selling drug in the world last year, with global revenue of $8.6 billion, according to IMS Health. Any competitor to it could have a shot at big sales.", "question": "Does the story commit disease-mongering?", "explanation": "The story does not exaggerate the dangers of any of the heart conditions the anti-platelet drugs are designed to treat. \u00a0 ", "answer": 1}, {"article": "\u201cThe aim of the study is very simple: can we detect changes in brain function before people are aware that they have them?\u201d\n\nResearchers recently pinpointed the significance of a tiny area of the brain known as the entorhinal cortex, which acts as a hub in a widespread brain network that controls navigation.\nNot all will be destined to be affected by the disease, however.\n\u201cBut difficulty with navigation is increasingly recognised as one of the very earliest symptoms.\nThe goal of the work is to help people as they develop the disease.\nAround 300 people, aged between 40 and 60, will be recruited to take part in the study.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "When she saw them, she said, \u201cI asked my analyst to rerun the data.\u201d\n\nNow, researchers say, the challenge is to find out why the test missed so many cancers, in particular, those on the right side of the colon, and whether the problem can be fixed.\nThe test also carries a small risk of perforating the bowel.\nIt looks for blood in the stool, which can arise from colon cancer.\nThey should take at least eight minutes to withdraw an endoscope from the colon.\nFlat and indented polyps tend to cluster in the right colon.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not exaggerate the seriousness or prevalence of colon cancer.", "answer": 1}, {"article": "\"The bottom-line finding of the Alpha Omega Trial is that [omega]-3 fatty acids did not reduce the primary endpoint major cardiovascular events,\" Kromhout said, noting that the ALA finding needs further confirmation.\nNone of the low-dose supplements seemed to stave off such events in most of the patients.\nAnd they're also not just looking at preventable fatalities but all heart-related events that follow.\nIt is during this acute post-attack period, he explained, when patients are most vulnerable to a subsequent event.\nAll had experienced a heart attack at some point in the decade leading up to the study, and all were taking blood pressure medications, anti-clotting drugs and statins.\n", "question": "Does the story commit disease-mongering?", "explanation": "\u00a0The story did not engage in over disease mongering.\n", "answer": 1}, {"article": "'Reduced infancy and childhood epilepsy following hypothermia-treated neonatal encephalopathy' by Xun Liu, Sally Jary, Frances Cowan and Marianne Thoresen in Epilepsia\nThe patients' cognitive performance, life quality and life expectancy is also affected by having the condition.\nAt two years, seven per cent of the children had an epilepsy diagnosis, however, far fewer, only two per cent, were on regular antiepileptic drugs.\nThe research found that babies, born after 2007, who received the cooling treatment, had much less epilepsy than before cooling treatment was introduced.\nBefore therapeutic hypothermia was introduced, poor outcome meaning death or moderate or severe disability was around 66 per cent (32 per cent death and 34 per cent surviving with disability).\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "Drinking cow\u2019s milk produced at night may be a treatment for anxiety and insomnia, suggests an animal study in the Journal of Medicinal Food.\n\nA glass of milk at bedtime has long been touted as a sleep aid. But the study found that milk collected at night, or night milk, had enhanced sedative effects in mice compared with milk produced during the day. Night milk significantly decreased the rodents\u2019 physical activity, balance and coordination and increased sleep time compared with day milk, the research showed.", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering going on here.", "answer": 1}, {"article": "The test, a CAT scan of the heart that measures plaque buildup in the arteries, is popular because heart disease, the nation's No.\nThe study offers the most definitive estimate yet of the cancer risk from the radiation exposure that comes with increasingly popular CT scans, which provide pictures of the heart's arteries and quantify the risk of heart attack in people without symptoms.\nThe scans are sometimes criticized as an example of expensive new technologies being adopted before proof is established that they're better than cheaper existing methods \u2014 an issue at the heart of the health care reform debate.\nDr. William Zoghbi, director of Methodist Hospital's Cardiovascular Imaging Institute, said the cancer risk numbers reported in the study are actually fairly low compared to other tests that take X-rays of the chest area, such as a regular CAT scan or coronary angiography.\nThey say the test's value is limited because it doesn't identify which plaque are stable and which could rupture and cause a heart attack.\n", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\n\nThe story notes that heart disease is the leading cause of death in the U.S., but it also points out doubts about whether screening with CT scans for calcium buildup in heart arteries can reduce the toll. ", "answer": 1}, {"article": "Newby and his team assessed how CTCA affected symptoms and quality of life six weeks and six months after the scan for 4,146 patients with suspected angina due to coronary heart disease.\n\u201cCertainly, this is something we now discuss in more detail with our patients, some of whom have declined CTCA.\u201d\n\n\u201cIt was striking for me that health status was very much related to receiving a (treatable) diagnosis or excluding such a diagnosis, rather than experiencing angina symptoms per se,\u201d said Dr. Paula M. C. Mommersteeg from the Center of Research on Psychology in Somatic Diseases, Tilburg University, The Netherlands, who has investigated associations between personality traits and coronary artery disease symptoms.\nWhen the CTCA results revealed something less than a blockage, so-called nonobstructive disease, as the cause for the patient\u2019s chest pain, patients\u2019 quality of life got worse in the following weeks and months.\nPeople who have coronary artery disease ruled out by the scan benefit, and so do those with severe blockages diagnosed, while those who have moderate artery disease confirmed may only become more anxious after the scan, researchers found.\n\u201cIf, however, a patient presents with atypical symptoms and is on no therapy, then the clinician needs to discuss with the patient the implications of potential CTCA findings, including nonobstructive disease that would mandate life-long preventative therapy,\u201d Newby said.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story reports that the researchers were looking at CTCA testing only for specific patients who had already been given a diagnosis related to chest pain. Readers would likely understand that the CTCA test was being offered only to certain patients to clarify their diagnoses, not something that would be recommended to people who were not already being tested or treated for chest pain that might be caused by heart disease. The article might have added a bit more clarification on who the test was intended to help.", "answer": 1}, {"article": "\"I really want to encourage clinical trials in this area because of its potential significance, but we have to be very careful in terms of safety data,\" Lajonchere said.\nThe long-term effects of the hormone are also uncertain.\nIt doesn't make a whole lot of sense,\" he pointed out.\nIt involved 13 adults, most of them men, aged 17 to 39.\nThere were, however, wide variations in individual responses, the team noted.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not resort to disease-mongering.", "answer": 1}, {"article": "Researchers have found that delivering a fecal microbiota transplant (FMT) in a pill\u2014a poop pill, basically\u2014is no worse than a similar procedure done with a colonoscopy.\n\u201cThe results are sort of a best-case scenario,\u201d she said.\n\u201cStool is such a complex mixture.\u201d\n\u201cFor this group of patients, nothing else really works,\u201d she said.\nWe just don\u2019t see kind of efficacy with drugs,\u201d Dr. Dina Kao told Newsweek.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "Still, little is known about its cause.\nThe authors suggest several biological mechanisms of breast milk may explain their results, including that breast milk contains many immunologically active components and anti-inflammatory defense mechanisms that influence the development of an infant\u2019s immune system.\nThe many potential preventive health benefits of breastfeeding should also be communicated openly to the general public, not only to mothers, so breastfeeding can be more socially accepted and facilitated.\nIn addition, more high-quality studies are needed to clarify the biological mechanisms underlying this association between breastfeeding and lower childhood leukemia morbidity,\u201d the study concludes.\nIn a review of all 18 studies, the authors found breastfeeding for six months or longer was associated with a 19 percent lower risk compared with no breastfeeding or breastfeeding for a shorter period of time.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release states that \u201cLeukemia is the most common childhood cancer and accounts for about 30 percent of all childhood cancers.\u201d \u00a0And it suggests that breastfeeding can prevent these leukemias, which has the potential to make mothers feel badly if they\u2019re unable to successfully breastfeed (a common phenomenon). But the release never provides the comforting information that cancer in children is, according to the National Cancer Institute, a \u201crare\u201d disease. This is important context.", "answer": 0}, {"article": "Varicose veins are one of the more unsightly signs of aging. But new, less-invasive treatments are making it easier to remove them painlessly, bypassing a difficult surgical procedure that was often the only option in the past.\n\nAs many as 25% of women and 15% of men suffer from varicose veins; over the age of 50, one out of two people are affected. Heredity plays a part, but obesity, prolonged standing on the job and hormone therapy increase the risks. Sometimes, varicose veins have no signs or symptoms and require no treatment,...", "question": "Does the story commit disease-mongering?", "explanation": "In some ways, this story gives varicose veins the appropriate weight. \u201cAs many as 25% of women and 15% of men suffer from varicose veins; over the age of 50, one out of two people are affected. Heredity plays a part, but obesity, prolonged standing on the job and hormone therapy increase the risks. Sometimes, varicose veins have no signs or symptoms and require no treatment, though doctors may recommend wearing compression stockings and elevating the legs. Exercise can also help relieve pain.\u201d Then it tips over into disease-mongering. \u201cBut often, varicose veins can be disabling and dangerous, as well as a warning sign of more serious problems in the circulatory system.\u201d\u00a0For the majority of people, this is merely a cosmetic issue, like wrinkles. The story also says, \u201cVeins near the surface of the skin can also rupture and bleed heavily.\u201d Our physician reviewer on this story wrote, \u201cI have never seen this or heard of it in my nearly two decades in medicine.\u201d", "answer": 0}, {"article": "Red and purple fruits owe their colors to...\nThe juice is a beautiful wine-red color and tastes delicious.\nMuch of the popularity is the work of a California-based company, Pom Wonderful.\nBut is it especially healthful?\nThe Pomegranate is hot.\n", "question": "Does the story commit disease-mongering?", "explanation": "This article did not contain obvious elements of disease-mongering.", "answer": 1}, {"article": "Dec. 20, 2010 -- Scientists using brain scanning technologies say they have been able to predict with 90% accuracy which children with dyslexia will be able to improve reading skills over a period of a few years.\n\nResearchers say their findings reveal activity in specific brain regions during reading that could eventually lead to new treatments for people with dyslexia.\n\n\u201cAt this time, we cannot say which treatment type will each child benefit from,\u201d study researcher Fumiko Hoeft, MD, PhD, an imaging expert at Stanford University, tells WebMD in an email. \u201cBut with more research, and if researchers combine it with intervention studies, then we should be able to identify brain patterns that are predictive of responding to one type of intervention or another.\u201d\n\nShe says in a news release that the study \u201cgives us hope that we can identify which children might get better over time\u201d and that the findings represent \u201ca huge step forward.\u201d\n\nThe discovery of brain regions involved in the learning disorder \u201cmay provide a mechanism for enduring improvement that promotes relatively successful reading development,\u201d according to the study, published in the Dec. 20 issue of the Proceedings of the National Academy of Sciences.", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\n\nWe would have liked to have seen a brief comment on the prevalence numbers quoted for dyslexia.\u00a0 While the numbers quoted are correct, the variation is dependent of the definition used and the testing methods.\u00a0 ", "answer": 1}, {"article": "Depression affects about 20 percent of people at some point in their lives.\nThey were later assessed by experts for their depression levels and the group that received genuine electroacupuncture was found to be a lot happier.\nThe electroacupuncture was given in addition to medication that the patients were already taking and meant to augment their treatment, Zhang told a news conference.\nAn imbalance in serotonin levels is believed to be linked to depression.\n\u201cWhen the acupoints are stimulated, some brain centres responsible for producing serotonin are stimulated,\u201d explained Ng, a consultant at the department of psychiatry at the Kowloon Hospital in Hong Kong.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease-mongering of depression in the story; neither was there much information about the study subjects except that they \u201chad suffered several bouts of depression in the last 7 years.\u201d\nThat\u2019s pretty broad.", "answer": 1}, {"article": "The study, \"Survival Outcomes in Men Undergoing Radical Prostatectomy after Primary Radiation Treatment for Adenocarcinoma of the Prostate,\" recently was published by Clinical Genitourinary Cancer, a peer-reviewed journal on the detection, diagnosis, prevention and treatment of genitourinary cancers.\n\"However, this study shows that it is a viable treatment option.\nRadiation therapy traditionally has been a primary treatment for the cancer, but one-fourth of men have a recurrence of prostate cancer within five years after the therapy.\nThis can bring a renewed hope and peace of mind to men living with prostate cancer.\"\nThe procedure is challenging because tissue that surrounds the prostate is scarred during radiation treatment, making it difficult for the surgeon to identify and cut out tissue that needs to be removed.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "Timothy Anderson, pharmaceutical analyst at Sanford C. Bernstein & Company, said in a recent note that Entresto was \u201clikely to become a mega-brand over time\u201d but that the initial uptake was \u201clikely to be on the slower side given the entrenched nature of off-patent ACE inhibitors.\u201d He said it was highly unusual that there were no major competitors for Entresto on the way, giving it a \u201clong runway.\u201d\n\nIn a clinical trial with more than 8,400 participants, patients were randomly assigned to take either Entresto or enalapril, an ACE inhibitor.\nBlacks and those with a previous history of the condition were at increased risk, it said.\nsaid that the main side effects were low blood pressure, high blood potassium levels and kidney impairment.\nPatients in both groups of the study could also take other drugs, such as beta blockers, as their doctors saw fit.\nAfter about 27 months, 21.8 percent of those taking Entresto had either died from cardiovascular causes or had been hospitalized for worsening heart failure, compared with 26.5 percent for those taking enalapril.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "\u201cWe have taken the job done by this equipment, which is the size of a large photocopier, and shrunk it down to a USB chip.\u201d\n\nThe test, which uses a mobile phone chip, requires a drop of blood to be placed onto a spot on the USB stick.\n\u201cMonitoring viral load is crucial to the success of HIV treatment.\nSome 36 million people worldwide are infected with the human deficiency virus (HIV) that causes AIDS, and the majority of them live in sub-Saharan Africa.\nAny HIV in the sample triggers an acidity change, which the chip transforms into an electrical signal.\nThis is sent to the USB stick, which shows the result on a computer or electronic device.\n", "question": "Does the story commit disease-mongering?", "explanation": "We didn\u2019t find any outlandish descriptions of HIV or AIDS.", "answer": 1}, {"article": "The study was funded by the Celladon Corp. of La Jolla, Calif.\n\"This is the first time gene therapy has been tested and shown to improve outcomes for patients with advanced heart failure,\" study lead author Dr. Donna Mancini, professor of medicine and the Sudhir Choudhrie professor of cardiology at Columbia University College of Physicians and Surgeons in New York City, said in a university news release.\n\"There are a lot of treatments for heart failure but at some point patients stop responding and then the prognosis is poor,\" said Dr. Rita Redberg, AHA spokeswoman and professor of medicine at the University of California, San Francisco.\nTUESDAY, Nov. 16, 2010 (HealthDay News) -- By substituting a healthy gene for a defective one, scientists were able to partially restore the heart's ability to pump in 39 heart failure patients, researchers report.\n\"The therapy works by replenishing levels of an enzyme necessary for the heart to pump more efficiently by introducing the gene for SERCA2a, which is depressed in these patients.\n", "question": "Does the story commit disease-mongering?", "explanation": "Although a quote from one of the researchers and another line in the body of the story refer to patients with \u201cadvanced heart failure,\u201d the headline and lead of the story refer to just \u201cheart failure,\u201d which includes a far broader range of people. A company news release defined the trial participants has having moderate to severe heart failure and significantly impaired pumping function of their hearts and less than half the normal ability to transport and utilize oxygen during exercise testing. The story should have been clear from the top about the severity of disease in the participants in this trial. A single additional sentence would have gone a long way in addressing this. ", "answer": 0}, {"article": "In a first, U.S. trial to test Cuban lung-cancer vaccine\n\u201cInstead of chemo being the backbone on which to improve, immunotherapy is now the backbone on which we build.\u201d\n\nLung cancer is the second-most-common malignancy in the United States, after breast cancer.\nH. Jack West, an oncologist at Swedish Medical Center in Seattle, said, \u201cIt is literally practice-changing \u2014 immediately.\u201d\n\nRoy Herbst, an oncologist at Yale Cancer Center said that most lung cancer patients now will be offered immunotherapy in some form much earlier than before.\nThe patients experienced a significantly longer period during which their disease did not worsen, compared with people who received only chemotherapy, said Memorial Sloan Kettering Cancer Center oncologist Matthew Hellmann, who led the study.\nThe studies simultaneously were published by the New England Journal of Medicine on a day that some experts called the \u201cSuper Bowl of lung cancer immunotherapy.\u201d\n\nThe reports underscore the increasingly important first-line role that immunotherapy, which unleashes the immune system to destroy cancer cells, is taking against the deadliest cancer.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering here. The story states that lung cancer is the \u201csecond-most-common malignancy in the United States, after breast cancer. The American Cancer Society estimates that 234,000 people will be diagnosed with the disease this year, and 154,050 will die of it.\u201d\nHowever, the story could have explained that about 140,000 of these patients have nonsquamous non-small cell lung cancer, the condition that is treatable with Keytruda.", "answer": 1}, {"article": "Records covered the use of both low- and high-dose aspirin (ranging from 75 milligrams to 500 milligrams), so-called \"nonselective\" NSAIDs (such as ibuprofen [Advil] and naproxen [Aleve]), and both older and newer types of COX-2 inhibitors.\nTing also advised that people consult with their doctor before starting on any blood thinner.\nFor more on NSAIDs and cancer, visit the U.S. National Cancer Institute.\nThe study appears in the May 29 online issue of the journal Cancer.\n\"Meanwhile, the most important prevention against skin cancer remains sun protection.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering.", "answer": 1}, {"article": "While there\u2019s evidence that this technique, known as transcranial magnetic stimulation (TMS), helps depressed people get better-and the US Food and Drug Administration has approved TMS for this purpose-many skeptics have questioned whether it really works, notes Dr. Mark S. George of the Medical University of South Carolina in Charleston, the lead author of the new study.\nIn a second phase of the study, all patients were given the real TMS treatment.\nThirty percent of the patients in the second phase recovered from depression.\nHow long the treatment should last is not yet clear.\nEighty-eight percent of the study participants completed the first phase of the trial.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story doesn\u2019t resort to disease-mongering.", "answer": 1}, {"article": "Christian\u2019s team studied 676 school-age children whose mothers had been in a clinical trial in which some got iron and folic acid supplements and other nutrients while they were pregnant.\n\u201cIron is essential for the development of the central nervous system,\u201d said Parul Christian, an expert in international health at the Johns Hopkins University Bloomberg School of Public Health, whose study appears in the Journal of the American Medical Association.\nCHICAGO (Reuters) - Children in rural Nepal whose mothers were given iron and folic acid supplements during pregnancy were smarter, more organized and had better fine motor skills than children whose mothers did not get them, U.S. researchers said on Tuesday.\nThe World Health Organization estimates that in developing countries, every other pregnant woman is anemic and about 40 percent of preschool children are anemic.\nAbout 80 percent of the children \u2014 aged 7 to 9 \u2014 were enrolled in school.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story says, \u201cIron deficiency is the most common and widespread nutritional disorder in the world, affecting 2 billion people, according to the World Health Organization.\u00a0Early iron deficiency can interfere with nerve development, biochemistry and metabolism, hampering both intellectual and fine motor development.\u201d It does not engage in disease-mongering. In fact, we would have liked to have seen a little more information about the problems associated with a lack of iron.", "answer": 1}, {"article": "The research falls short of concluding marijuana helps wean people off opioids - Vicodin, Oxycontin and related painkillers - and heroin, though.\n\"We are in the midst of a serious problem.\nI couldn't get anything done,\" Ham said.\nIt's a tempting sell in New England, hard hit by the painkiller and heroin crisis.\nHam gave it a try in 2013 and said the pain is under control and she hasn't gone back on the opioids.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no obvious disease mongering in this story. Opioid addiction is real and very problematic.", "answer": 1}, {"article": "With statins you get toxicity \u2013 with these drugs we don\u2019t see any side effects with the antibody.\u201d\n\nIn an accompanying editorial, authors Dr. Stephen G. Young, and Loren G. Fong, Ph.D. write: \u201cAt this point, the status of PCSK9 therapeutics appears to be full speed ahead.\nA control group of subjects with nonfamilial high cholesterol was treated only with a special diet.\n\u201cThis is a hot research area and everybody is so close together.\"\nAll of those subjects were also receiving treatment with the statin Lipitor.\nThis new drug is being developed by Regeneron Pharmaceuticals and Sanofi, who funded the research.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering.", "answer": 1}, {"article": "Scientists say they have created a new drug that can attack ovarian and lung cancers in patients for whom other treatments have failed.\nThe cocktail also stopped the cancer growing for almost six months, which is unexpected for patients with advanced-stage cancers who were unresponsive to currently available treatments, including chemotherapy, the authors said.\nDr. Susana Banerjee, consultant medical oncologist at The Royal Marsden NHS Foundation Trust and team leader in gynecological cancers at ICR, who is leading the phase II trial, commented in a statement: \u201cEffective treatment options for women with relapsed ovarian cancer are limited, so these results are very encouraging.\nIt built on previous research by the ICR that showed ovarian cancer cells resistant to treatment generally have higher levels of a molecule called p-S6K, which aids the growth of the disease.\nThe U.K.-based researchers used a new drug along with chemotherapy medication known as paclitaxel on 25 women with high-grade, serous ovarian cancer, and 40 participants with squamous non-small cell lung cancer.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not exaggerate the prevalence of these cancers, though it would have been useful to provide some numbers on how many women develop metastatic ovarian cancer that doesn\u2019t respond to current treatments.", "answer": 1}, {"article": "'This is not the end': Using immunotherapy and a genetic glitch to give cancer patients hope\nIf approved, such treatments are expected to command stratospheric prices.\nAlmost immediately, he began producing the missing clotting factor.\nBleeding episodes \u2014 which can result from injury or occur spontaneously \u2014 can cause extensive damage and be life threatening.\nThere he would inject himself with refrigerated blood-clotting factor to prevent internal bleeding and extensive bruising and swelling.\n", "question": "Does the story commit disease-mongering?", "explanation": "The treatment described here, if ultimately proved worthy, could have a profound impact on a serious genetic condition.", "answer": 1}, {"article": "Maryjane Wraga , associate professor of psychology at Smith College in Northampton, tested 54 women for spatial reasoning skills -- the ability to solve problems related to shape and measurement.\nA second group received a positive message, and the control group received no message.\nCAUTIONS: The study looks only at spatial reasoning.\nA group of 11,711 men with hypertension were surveyed about their drinking habits every four years from 1986 to 2002.\nThe negative-message subjects made 14 percent more errors than the positive, with the control subjects falling in between.\n", "question": "Does the story commit disease-mongering?", "explanation": "The study does not exaggerate the prevalence or seriousness of heart disease.", "answer": 1}, {"article": "\u201cThis is an important step in diabetes control because it shows that, with this system, people can sleep safely with minimized risk of hypoglycemia,\u201d said Dr. Eric Renard, a professor of diabetology at Montpellier University Hospital in Montpellier, France.\nNo children in the study who were treated with the computer-assisted system experienced very low blood sugar overnight.\nThe goal is a portable system that could be worn on a belt and would be no larger than a cellphone.\nAnd the experimental combined system itself was not fully automated.\nDr. Renard, whose commentary accompanied the study in The Lancet, has been a consultant and speaker for several makers of diabetic products, he said.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not exaggerate the effects of type 1 diabetes.", "answer": 1}, {"article": "It\u2019s a single.\u201d\n\nSaying that even a single was helpful, Dr. Kahl was part of a majority on the panel that recommended approval of the drug, 10 to 4.\nIn the clinical trial that led to approval of the drug, 27 percent of the 109 patients experienced a reduction in tumor size.\nBut considering all the patients in the trial, only 12 percent had a reduction in tumor size that lasted for more than 14 weeks.\nSo the total cost of using Folotyn will be less than for many other drugs with lower monthly prices.\nIn the clinical trial, the median duration of use was 70 days, which would cost roughly $70,000 to $80,000.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story accurately represents the seriousness and prevalence of peripheral T-cell Lymphoma, which is quite rare and serious.", "answer": 1}, {"article": "TUESDAY, May 4, 2010 (HealthDay News) -- Noninvasive stool DNA testing can detect two types of colorectal precancers and could play a larger role in colon cancer prevention, say two new studies.\nSome of the study authors and the Mayo Clinic have a financial interest related to technology used with this research.\n\"The 90 percent detection rate by stool DNA testing is remarkable.\nIt's important for people with IBD because they are at much higher risk for colorectal cancer than the general population.\nUnlike common polyps, they tend to be flat and the same color as the colon lining.\n", "question": "Does the story commit disease-mongering?", "explanation": "No overt disease-mongering. ", "answer": 1}, {"article": "LONDON (Reuters) - First results from a human trial of an Ebola vaccine from GlaxoSmithKline show it is safe and generates an immune response, scientists said on Wednesday, but larger trials are needed to see if it protects and if a booster is needed.\nHowever, the antibody response was weaker than was found in a trial of the same Ebola vaccine in macaque monkeys, in which the animals were also found to be protected.\nThe vaccine is being developed by the U.S. National Institutes of Health (NIH) and GSK against the Zaire strain of Ebola \u2014 the one circulating in West Africa \u2014 and the first doses for a larger trial arrived in Liberia last week.\nThe data, published in the New England Journal of Medicine, were from 60 healthy volunteers given the vaccine in Britain between Sept. 17 and Nov. 18 last year.\nThat trial is the first of several mid-stage studies planned for West Africa and aims to test GSK\u2019s vaccine and one from Merck and NewLink.\n", "question": "Does the story commit disease-mongering?", "explanation": "Given the near hysteria that resulted in the US cases of Ebola, it would have been very easy to fall victim to disease mongering. But this story didn\u2019t.", "answer": 1}, {"article": "But he also sees a lot of patients who cannot be candidates.\nSo the take-home message: If you're over 60 and you begin to experience visual loss, get yourself to an eye specialist as soon as possible to see if you can be treated with medication to stabilize and even reverse the vision loss you've experienced.\n\"In order to implant this device, we need to remove the natural lens, or the cataract, and then use a portion of the natural lens to position and support the telescope,\" says Williams.\nThat's why Orr saw blank spots where people's noses and eyes should be in their faces, sort of like \"holes in the film,\" says Colby.\nBut if they're scanning the room to see exactly where the clock is, they use the other eye, which also has end-stage macular degeneration.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story starts out by saying the procedure \"could help millions of older adults who are nearly blinded by macular degeneration.\" This isn\u2019t quite disease mongering, and, if we look at the disease globally, that\u2019s potentially true. In the U.S. alone, according to the American Health Assistance Foundation, about 1.75 million Americans age 40 who suffer from acute macular degeneration. But the story then makes it clear that not all of them would be candidates for this procedure. Given that \"millions\" are used in the lead, it would have been smart to follow up with a more realistic number of how many might actually benefit.", "answer": 1}, {"article": "\"What we've had available the last 16, 17 years has made a big difference,\" Richert says, \"and what we have coming onboard now, these are going to make even a larger difference.\n\"This is a very scary disease.\nHe says the discovery shook his world.\nThe main benefit of the pills will be that they are easier to take.\nThe new pills also appear to be more effective than most current drugs.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering. ", "answer": 1}, {"article": "\"Symptoms of a concussion, or a mild to moderate traumatic brain injury, can be subtle and are often delayed, in many cases by several days,\" said Linda Papa, MD, MSC, an emergency medicine physician and NIH funded researcher at Orlando Health and lead author of the study.\nResearchers analyzed nearly 600 patients for 3 years.\nWe think this test could change that,\" she said.\nThese proteins are found in glial cells, which surround neurons in the brain, and when an injury occurs, the GFAP are released.\nAlmost all concussions in children are diagnosed only by symptoms, which are either observed, like vomiting or loss of balance, or symptoms reported by the child, like blurred vision or headaches.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release does not include disease mongering.", "answer": 1}, {"article": "Master said each participant was asked to carry an accelerometer to record movements and an iPod Touch loaded with an app that would ping them prompts at intervals during each day to report any symptoms they were feeling. They also completed activity questionnaires and summaries. In addition, they wore a device called an ActiGraph to monitor sleep.", "question": "Does the story commit disease-mongering?", "explanation": "The story does not appear to engage in disease mongering. However, it would have been helpful to let readers know how common youth concussions are in addition to noting the recent rise in diagnosed cases.", "answer": 1}, {"article": "Using space age technology in the Sports Ready clinic at Medway Park, Gillingham, Dr Karen Hambly, an international expert on knee rehabilitation, works with clients who have been given the all clear to start to return to sporting activities but may have concerns about moving from being a patient with an injury to being an athlete again.\nThe cartilage covering the bone surface is not able to heal itself when it is damaged and this is why surgical procedures are available to repair the damaged area.\nWhen people run, the load on their knee joints can be up to five times greater than when walking.\nPatients recovering from knee operations are being helped back to sport and exercise through expert rehabilitation at the University of Kent.\nHealthy cartilage that covers the bone surfaces in the knee joint transfers these high loads from the lower leg to the upper leg.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "This article is featured in Newsweek's Special Edition: Nature's Remedies\u2014Heal Your Body.\nThe brain\u2019s synapses control how much of these chemicals are released, and drugs like Zoloft effectively prevent the little serotonin being produced from reabsorbing back into the nerve cells from which they were released, resulting in a higher concentration of serotonin.\nBut the point is that if we can identify the circuit that causes the symptoms, we can target that circuit and make it function better through brain stimulation.\nIn fact, the only clue TMS treatment contains magnets at all is that patients must remove any jewelry and stow their credit cards (to prevent demagnetization) before treatment.\nAccording to the Anxiety and Depression Association of America (ADAA), 15 million adults\u2014approximately 6.7 percent of the population\u2014suffer from major depressive disorder, which is most often treated through a combination of talk therapy and medication.\n", "question": "Does the story commit disease-mongering?", "explanation": "Serious depression is a killer, and treatments are not consistently effective for many people. But the story misleads with its description of depression.\nFirst, the story relates\u00a0the old neurotransmitter deficit idea\u2013specifically that of serotonin\u2013which has largely been debunked.\nWe also take issue with the first line of the article: \u201cOne of the leading causes of disability in the United States isn\u2019t physical\u2014it\u2019s mental.\u201d\nMental illness is indeed physical, as the article even mentions when it discusses the \u201cphysical\u201d brain changes later in the story.", "answer": 0}, {"article": "\"The results of our analysis are especially important for patients, given that many ARBs are now also generic, which reduces their costs,\" he added.\nAngiotensin II restricts blood flow through vessels, raising blood pressure.\nAlthough ACE inhibitors were developed 10 years earlier, both types of drugs showed similar effects in the analysis, challenging previous findings that suggest ACE inhibitors have greater benefits.\nFor more about blood pressure drugs, visit the American Heart Association.\nHowever, when trials were conducted at similar times, one drug was not more effective than the other, the findings showed.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story does not appear to commit disease-mongering.", "answer": 1}, {"article": "That's when they learned cocoa compounds named epicatechin monomers enhanced beta cells' ability to secrete insulin.\nBut here's the thing: BYU researchers have discovered certain compounds found in cocoa can actually help your body release more insulin and respond to increased blood glucose better.\n\"These results will help us get closer to using these compounds more effectively in foods or supplements to maintain normal blood glucose control and potentially even delay or prevent the onset of type-2 diabetes,\" said study co-author Andrew Neilson, assistant professor of food science at Virginia Tech.\n\"You probably have to eat a lot of cocoa, and you probably don't want it to have a lot of sugar in it,\" said study author Jeffery Tessem, assistant professor of nutrition, dietetics and food science at BYU.\nWhile there has been a lot of research on similar compounds over the past decade, no one has been able to pinpoint which ones are the most beneficial or how exactly they bring about any benefit -- until now.\n", "question": "Does the news release commit disease-mongering?", "explanation": "Diabetes is a widespread and serious health threat. However, the careless wording of this news release (and the skewed news coverage it encourages) could well mislead people who do not have diabetes to use the headlines as an excuse to eat more chocolate. The implication of the news release is that this compound can be given to people at risk of developing type 2 diabetes with the goal of delaying their \u201cdescent\u201d into overt diabetes, but this could lead to over-treatment of mild diabetes.", "answer": 1}, {"article": "Dec. 6, 2010 -- Taking aspirin over a long period of time can substantially cut the risk of dying from a variety of cancers, according to a study showing that the benefit is independent of dose, gender, or smoking.\nIt also found that the protective effect increases with age.\nThe investigation also showed that the benefits of taking aspirin increased over time.\nThe protective effect of taking low doses of aspirin varied according to the type of cancer and how long aspirin had been taken, the authors found.\nAfter five years, death rates were shown to fall by 34% for all cancers and by 54% for gastrointestinal cancers.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease-mongering.", "answer": 1}, {"article": "Please use our search feature and update your bookmarks. Thank you!", "question": "Does the news release commit disease-mongering?", "explanation": "No fear mongering here.", "answer": 1}, {"article": "For its part, the pediatricians group hopes the new recommendations will encourage more parents to circumcise their sons \u2014 and more insurance plans to pay for it.\nThey liken the procedure to female genital mutilation.\n\"Those families who choose circumcision should have access to circumcision.\nIt's all the same couple of studies that have been regurgitated and reprogrammed.\n\"It drops the risk of heterosexual HIV acquisition by about 60 percent.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not commit disease mongering.", "answer": 1}, {"article": "And in an earlier Lilly-sponsored phase-3 trial, ixekizumab was shown to be effective for psoriatic arthritis patients who had not yet been treated with biologic drugs such as TNF inhibitors.\nThe drug, an injectable monoclonal antibody, is already commercially available for the treatment of psoriasis, for which it has been remarkably effective, said Genovese.\nFor the last decade or so, Genovese said, another pro-inflammatory substance called IL-17 has been drawing the attention of immunologists focusing on psoriasis and psoriatic arthritis.\nHowever, despite the availability of TNF inhibitors, \u201conly about half of psoriatic arthritis patients who are given TNF inhibitors get better,\u201d said Genovese.\nAlthough the ultimate cause of the disease remains unknown, there was a good clinical rationale for hoping it might be responsive to ixekizumab.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering. The release provides strong context on the condition as well as how the drug is believed to work.", "answer": 1}, {"article": "In this study, after 12 months, it\u2019s a 9-in-10 chance.\u201d\n\nThe men in the study were aged 45 to 80 with medium- to high-risk cancer, and would likely have undergone surgery or radiotherapy down the line.\nProstate cancer is the most common cancer among men.\nFewer side effects would also lower other health care costs, he said.\nNone of the patients reported urinary incontinence a year after treatment, and only 1 in 10 suffered from poor erections.\nThe new study, designed as a proof-of-concept study, involved just 41 men.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering.", "answer": 1}, {"article": "\u201cThe number of dementia cases could drop by half.\u201d\n\nNov. 20: MRI scan may predict which people will develop Alzheimer's disease\n\nLambracht-Washington said the study marks major progress toward a safe and effective vaccine.\nThere has been research in monkeys and rabbits as well, and the researchers hope the vaccine will progress to human trials.\nThe number could double by 2050.\nTesting in mice showed that the vaccine safely prevents the buildup of substances in the brain associated with the fatal disease, the team reported this week in the journal Alzheimer's Research & Therapy.\nAbout 5.7 million Americans have Alzheimer's disease, according to the University of Texas.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering here.", "answer": 1}, {"article": "Using the two drugs together as a one-two punch may be even more powerful.\nPaul Workman, professor and chief executive of the Institute of Cancer Research in London, said in a statement accompanying the publication of the journal article that \"the evidence on aromatase inhibitors has been accumulating for well over a decade, but it has taken this huge and complex study to make sense of all the data, and provide a firm basis for clinical guidelines.\u201d\n\n\"It tends to be the discovery of new treatments that grabs the headlines, but it is just as important to maximize the benefit patients get from existing treatments through major, practice-changing studies like this,\" Workman said.\nThe study reported that \"taking aromatase inhibitors for 5 years reduced the risk of postmenopausal women with breast cancer dying of their disease by 40 percent within 10 years of starting treatment, compared with no hormonal treatment.\"\n\u201cThe drugs are complementary, because the main side effect of aromatase inhibitors is an increase in bone loss and fractures, while bisphosphonates reduce bone loss and fractures as well as improving survival,\" he said.\nA separate analysis by the same group, also published in The Lancet, looked at bisphosphonates, which are typically used for osteoporosis.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering in this article. Although, as noted above, we think there\u2019s some\u00a0\u201ctreatment mongering\u201d going on both the headline and closing quote from a researcher who says,\u00a0\u201cThe drugs are complementary, because the main side effect of aromatase inhibitors is an increase in bone loss and fractures, while bisphosphonates reduce bone loss and fractures as well as improving survival.\u201d These two drugs are commonly prescribed together but the study does not address their use in combination. If the story is going to focus on an issue that wasn\u2019t even addressed in the studies being reported on, we think it\u2019s essential to include a statement from an independent expert about that suggestion.", "answer": 1}, {"article": "Dr. Bremner said he typically suggests a trial of therapy for up to a year to see if sexual function or other symptoms improve.\nCurrently, we\u2019re in limbo as to how to advise patients.\u201d\n\nHe acknowledged that the need for such a study for men is \u201cless compelling\u201d because, in contrast to women, who experience an abrupt drop in estrogen at menopause, often with disruptive symptoms, hormone decline in aging men is far more gradual, and symptoms, when they occur, are commonly viewed as normal signs of aging, not hormone deficiency.\nAlthough low hormone levels are widely thought to increase a man\u2019s risk of depression, the researchers found that \u201cpsychological symptoms had little or no association with the testosterone level.\u201d\n\nThere are four main approaches to testosterone therapy available in this country: intramuscular injections every one to three weeks; skin applications through a patch or gel; and pellets implanted under the skin that last for months.\nThe risk of prostate cancer is of greater concern, given that suppressing the body\u2019s natural production of testosterone can cause this cancer to regress.\nThe most common reason men seek testosterone therapy is waning sexual desire or performance, although the ability of the hormone to relieve sexual symptoms is unpredictable.\n", "question": "Does the story commit disease-mongering?", "explanation": "The\u00a0concept of male \"andropause\" bears many of the hallmarks of disease-mongering.\u00a0Low testosterone is\u00a0common in\u00a0aging men and has never been conclusively shown to cause the symptoms \u2014 such as low sexual desire and erectile dysfunction \u2014 that are typically attributed to it. So offering treatment for this \"condition\" can be seen as an unwarranted medicalization of\u00a0the normal\u00a0aging process.\nThis article edges toward the line when it suggests that men being treated in one study\u00a0had experienced \"a decrease in energy, mood, vitality and\u00a0sexuality as result of low testosterone levels.\" The evidence linking these\u00a0symptoms to low\u00a0testosterone levels comes from observational studies that cannot prove cause and effect.\u00a0\u00a0And many studies show that such non-specific symptoms\u00a0can\u00a0be caused by\u00a0chronic diseases,\u00a0such heart disease and diabetes,\u00a0which are\u00a0also common in aging men with low testosterone.\u00a0These chronic diseases can also cause testosterone levels to decrease. This doesn\u2019t mean that low testosterone is responsible for the symptoms, or that\u00a0testosterone therapy will alleviate them.\u00a0\nThis\u00a0questionable\u00a0assertion notwithstanding, the article overall\u00a0does a good job of\u00a0presenting conflicting evidence on the subject. Elsewhere in the story it is noted that sexual performance and desire are not reliably linked to testosterone levels. And the story notes\u00a0that any parallel to menopause \u2014 a comparison often made by supporters of testosterone therapy \u2014 is\u00a0tenuous at\u00a0best, since the\u00a0hormone decline experienced by men is far more gradual and the symptoms are less disruptive.\u00a0\u00a0\u00a0\u00a0", "answer": 1}, {"article": "\u201cWhen this study was started the average life expectancy of someone with advanced melanoma was 11 months and now we're seeing that a large percentage of people are living at least three years.\u201d\n\nKeytruda \u2014 known generically as pembrolizumab \u2014 targets the activity of genes called PD-1 (anti-programmed-death-receptor-1) and PD-L1.\nThere are side-effects, including fatigue, itchiness and rash.\nThat means 60 percent of patients are not living that long \u2014 but it\u2019s still far more than the usual 11-month survival with advanced melanoma.\nThe interaction between the two genes lets some tumors escape detection and destruction by immune system cells.\nHe says there\u2019s no trace of his cancer now.\n", "question": "Does the story commit disease-mongering?", "explanation": "We didn\u2019t see any gratuitous or frightening description of melanoma\u2019s many symptoms or treatment side effects.", "answer": 1}, {"article": "(Reuters Health) - - Exhausted shift workers may be safer driving home at night when they\u2019re exposed to bright light before they hit the road, a small study suggests.\nShift workers with chronic sleep deprivation also face an increased risk of accidents.\nTo test the effect of light therapy on driving, researchers did a series of three experiments with 19 adults.\nExposure to bright light didn\u2019t appear to improve reaction times or sleepiness.\nNone of the people who slept at home crashed, and neither did any of the sleep-deprived people who got bright light therapy before getting behind the wheel, the study found.\n", "question": "Does the story commit disease-mongering?", "explanation": "Sleepy drivers are dangerous drivers, so this study focuses on a real risk.", "answer": 1}, {"article": "One of the new studies, published today in the New England Journal of Medicine, tested the ring in more than 2,600 women in four countries \u2014 Malawi, SouthAfrica, Uganda, and Zimbabwe \u2014 over nearly two years.\n\u201cThere is absolute reason to celebrate.\n\u201cWe obviously always want higher numbers.\nLike birth control, the more types of HIV prevention, the better, experts say.\nFor others, that may be not achievable,\u201d Baeten said.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "With knee-replacement surgery on the rise, more patients with two bad knees are opting for a controversial procedure that replaces both at the same time.\n\nSimultaneous bilateral knee replacement, as the surgery is known, is a subject of debate among orthopedic surgeons, with conflicting evidence about the risks and benefits. Proponents say it eliminates the need for a second hospital stay and grueling rehabilitation period, reduces time spent under anesthesia and costs less.", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "\u2018\u2018There is no chance that for these patients, that chemotherapy would have any benefit.\u2019\u2019\n\nDr. Karen Beckerman, a New York City obstetrician diagnosed with breast cancer in 2011, said she was advised to have chemo but feared complications.\nResults on these groups are not yet ready \u2014 the study is continuing.\nAfter five years, about 99 percent had not relapsed, and 98 percent were alive.\nEach year, more than 100,000 women in the United States alone are diagnosed with this.\n\u2018\u2018I was convinced that there was no indication for chemotherapy.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering in this article.", "answer": 1}, {"article": "The findings build on a 2015 UCLA study that demonstrated that both green tea and black tea helped prevent obesity in mice that consumed a high-fat, high-sugar diet.\n\"For black tea lovers, there may be a new reason to keep drinking it,\" she said.\nIn the mice that consumed either type of tea extract, there was less of the type of bacteria associated with obesity and more of the bacteria associated with lean body mass.\nThe research is published in the European Journal of Nutrition.\nAccording to Henning, the molecules in green tea are smaller and can more readily be absorbed into the body and reach the liver directly, while black tea molecules are larger and stay in the intestine rather than being absorbed.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering here.", "answer": 1}, {"article": "Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities.\nIn a study of 195 asymptomatic women with dense breast tissue who had a negative mammogram within the previous 11 months, AB-MR detected five additional cancers after a negative screening mammography, according to preliminary findings from a Penn Medicine team presented this week at the Radiological Society of North America meeting in Chicago.\n\"Having dense breast tissue makes it more difficult to detect a cancer on a mammogram,\" said the study's lead author, Susan Weinstein, MD, an associate professor of Radiology and the director of breast MRI at Penn Medicine.\nThe School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2016 fiscal year.\nThe most common exam offered for asymptomatic patients seeking supplemental screening is a whole breast screening ultrasound examination.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release veers into disease mongering when it drops in the comment that \u201cOne in eight women in the United States will develop breast cancer at some point during their life.\u201d That\u2019s a jarring statistic that rarely fails to get attention. But to add perspective, consider what the National Cancer Institute notes about a woman\u2019s lifetime risk of developing breast cancer: \u201ca woman born today has about a 1 in 8 chance of being diagnosed with breast cancer at some time during her life. On the other hand, the chance that she will never have breast cancer is 87.6 percent, or about 7 in 8.\u201d [Emphasis added.]\nAnd as noted above, it would have been helpful if the release had stated how many cancers versus DCIS were found through the abbreviated MRI.\u00a0  ", "answer": 0}, {"article": "(Reuters) - Pivotal trial results for Merck & Co Inc\u2019s immunotherapy drug Keytruda show that it lengthened survival by three months, or nearly 40 percent, for patients with advanced bladder cancer who had stopped responding to chemotherapy.\nThe Merck drug is awaiting U.S. Food and Drug Administration approval, but Tecentriq was approved by the agency last year, contingent on verification of its clinical benefit.\nAfter 18 months, 36 percent of Keytruda patients were alive, compared with 20.5 percent of chemotherapy patients, according to research published by ASCO.\nThe company is currently enrolling patients in a phase three trial of Keytruda, combined with chemotherapy, as an initial treatment for bladder cancer.\nThe study did not detect a difference in the length of time patients lived without their disease getting worse.\n", "question": "Does the story commit disease-mongering?", "explanation": "This is a barely passing satisfactory. Some numbers on how common advanced bladder cancer is, and its mortality rate for standard treatment, would have been useful.", "answer": 1}, {"article": "CHICAGO -- The diabetes drug Actos was able to slow the progression of plaque buildup in artery walls, while an older diabetes drug failed to stop the progression in patients with diabetes and coronary-artery disease, according to a study released Monday.\n\nUntil now, no diabetes-therapy regimen has been shown to reduce the progression of coronary atherosclerosis within the arterial walls among patients with Type 2 diabetes, a disease characterized by high blood-glucose levels that result from the body's inability to use insulin.", "question": "Does the story commit disease-mongering?", "explanation": "The story does not exagerrate the seriousness or prevalence of diabetes or atherosclerosis. The story could have done more to distinguish the surrogate outcome of plague buildup from actual cardiovascular outcomes.", "answer": 1}, {"article": "Cancer cells remain elusive and tough to locate, but a new crop of nuclear-imaging tests promises to lead to more accurate prognosis and treatment.\n\nThe tests use imaging agents that combine radioactive isotopes with targeted molecules that can spot cancer at the cellular level. The ability to accurately locate the cancers helps physicians make better and earlier diagnoses\u2014and may eventually make possible targeted nuclear-medicine therapies that identify and kill cancer cells, but not the surrounding healthy cells.", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering.", "answer": 1}, {"article": "The women were followed for an average of about 3.5 years.\nRoughly half of the women in the study had undergone either mastectomies (surgery to remove their breasts) or salpingo-oophorectomies (surgery to remove the ovaries and fallopian tubes) between 1974 and 2008, in order to proactively lower their risk of cancer.\n\"One of the main messages of our study is that salpingo-oophorectomy should be part of any management plan for any woman who is found to have these genetic mutations,\" said Rebbeck.\nWomen who carry these mutations have a lifetime risk of breast cancer of anywhere between 56 percent to 84 percent, according to the researchers, whereas the risk for ovarian cancer ranges from 36 percent to 63 percent for BRCA1 mutation carriers and 10 percent to 27 percent for BRCA2 mutation carriers.\nBy contrast, the lifetime risk of breast cancer among women generally is about 12 percent, and for ovarian cancer, it's less than 2 percent.\n", "question": "Does the story commit disease-mongering?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story makes clear that the study findings are relevant specifically to women who have been told that they carry BRCA1/2 genetic mutation that substantially increase their risk of cancer. It compares the lifetime risk estimates of women with the mutations and those in the general population. It also includes comments from experts saying that women who have a family history of cancer should talk to their physicians about whether they should consider genetic testing, thus highlighting the distinction between family history and the specific gene mutations looked at in this study. Also, as mentioned in the summary, the gene mutations are present in less than 3 percent of women who have just a single relative who had breast cancer, so the quote urging all women with a family history of breast cancer presents an extremely aggressive position.", "answer": 1}, {"article": "With better drugs and radiation techniques available, the proportion of women with Stage 4 breast cancer who had surgery dropped from 67.8 percent in 1988 to 25.1 percent in 2011, according to a study published Wednesday in the journal JAMA Surgery.\nOver the past few decades, as breast cancer has increasingly been treated as a systemic disease, the number of surgeries performed on the most serious cases has plummeted.\nBut with better therapies to control the cancer systemically and improved imaging that finds ever-smaller deposits of cancer in other parts of the body, it may be time to see whether surgery also can help increase the length of survival times, they said.\n\"Aggressive local therapy may benefit select women, such as those with an already established potential for durable remission,\" they wrote in their paper.\nAs other research has shown, African American women were over-represented among women who have Stage 4 breast cancer at the time they are first diagnosed.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article does not engage in disease mongering, although it could have been helpful to learn more about the prevalence of breast cancer in the US.", "answer": 1}, {"article": "\"We wouldn't want to be encouraging people to drink that much [coffee], without people considering the other risks factors,\" Hashibe says.\nIt\u2019s not exactly known why coffee may help prevent these cancers.\nCoffee did not decrease the risk of a third type of oral cancer \u2013 laryngeal cancer.\n\"Each person needs to think about how they metabolize caffeine or coffee.\"\nHe suggests \u201cconsuming coffee, tea, veggies, and fruits rather than doing just one thing.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "No overt disease-mongering in the story. ", "answer": 1}, {"article": "Now Harvard researcher Michael E. Weinblatt, MD, reports results from a phase II clinical trial in which 457 patients with active rheumatoid arthritis despite methotrexate treatment received R788 or placebo for six months.\nWomen with breast tumors have low levels of Syk.\nNormally, the Syk enzyme helps suppress tumors.\nFor now, R788 looks very promising, the researchers report.\nThere's at least one theoretical concern about R788.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story avoids disaease mongering.", "answer": 1}, {"article": "So it really is extraordinarily helpful for people.\u201d\n\u201cIt would take my heart away when I was trying to eat and I\u2019d look up and they were looking at me.\u201d\n\nSamuels, 72, has essential tremor, a movement disorder characterized by uncontrollable shaking mostly in the hands or legs.\nIt\u2019s a pretty high incidence of side effects,\u201d said Dr. Ho, who is the director of the Movement Disorders Program at Tufts Medical Center.\nI can eat like a normal person, doing things that I couldn\u2019t do before.\u201d\n\nIn July, the Food and Drug Administration approved the device being used in the trial.\nThat needs to be shown.\u201d\n\nThe researchers are in the process of collecting this data; the clinical trial will run until December.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story cites a figure from the International Essential Tremor Foundation, an advocacy group, that an estimated 10 million people in the United States suffer from the condition. However, a 2014 analysis of existing research put the number of cases at around 7 million as of 2012, or about 2.2% of the U.S. population. While this may not qualify as disease mongering, the story could have pointed out that the exact number of cases isn\u2019t clear. Also, the story should have noted that not all people with essential tremor have symptoms severe enough to require treatment.", "answer": 1}, {"article": "\"Our findings show that a text messaging program helped some groups of pregnant women quit smoking during pregnancy,\" says lead author Lorien C. Abroms, ScD, MA, an associate professor of prevention and community health at Milken Institute School of Public Health (Milken Institute SPH) at the George Washington University.\nQuit4baby is targeted to smoking cessation and sends more text messages--between 1 and 8 per day aimed at bolstering a pregnant woman's resolve to quit.\nAfter three months, 16 percent of the women who were enrolled in both Text4baby and Quit4baby had quit compared with just 11 percent of women getting just Text4baby.\nThe messages help educate the women about the health risks associated with smoking and they are interactive--allowing a woman to text back for more help if she is experiencing a craving or goes back to smoking.\n\"The study's findings suggest a potential new quitting strategy, especially for those later in their pregnancies and older pregnant women.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here. Risks to fetuses from smoking are real.", "answer": 1}, {"article": "The latest health and science updates, breakthroughs, research, and the best in investigative and informative journalism.", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in overt disease mongering.", "answer": 1}, {"article": "Says Likosky: \"If you cool the brain down, it may be that it uses less energy and (is) less likely to damage itself over that first 24 hours.\"\nIt's a story that still gives Cowles chills.\nResearch has shown it can improve the survival rate by 14 percent.\nIt requires training and a lot of coordination.\nThe idea is that cooling a comatose patient after a heart attack prevents brain damage.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not overtly engage in disease mongering.", "answer": 1}, {"article": "\u201cThere\u2019s definitely a major need for a permanent, total artificial heart,\u201d Laman A.\nThe Lasker Foundation, which is based in New York, praised their work in the development of artificial heart valves, saying they had \u201cprolonged and enhanced the lives of millions of people with heart disease.\u201d\n\nIn the November 2009 bulletin of the Acad\u00e9mie Nationale de M\u00e9decine, Dr. Carpentier wrote that, instead of picking up from older models of artificial hearts built on animal research, the developers of the new device had sought to use the tools of the digital revolution, namely computer-assisted design, hemodynamic modeling, regulation algorithms and simulations.\nThe United States Food and Drug Administration has designated the AbioCor as a \u201chumanitarian use device,\u201d meaning its use is restricted to people who are ineligible for transplants and would otherwise be facing imminent death.\nCiting World Health Organization data that shows heart disease is the world\u2019s leading cause of death, Mr. Conviti, the Carmat chief executive, estimated the potential market at \u201ca minimum\u201d of 100,000 patients a year in the United States and Europe.\nIn the United States, the National Heart, Lung and Blood Institute, a unit of the National Institutes of Health, is supporting efforts by two separate groups, one led by Dr. O. H. Frazier of the Texas Heart Institute in Houston, the other by Dr. Leonard A. R. Golding of the Cleveland Clinic.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story concludes:\u00a0\nThe broad \"heart disease as leading cause of death\" is not directly applicable to the target population for an artificial heart.\u00a0 One woman\u2019s single vessel coronary artery disease \u2013 which qualifies as heart disease \u2013 is not another person\u2019s end-stage heart failure. So even with the qualifying followup comments from the company exec, the story let him get away with a disease-mongering premise to start with. ", "answer": 0}, {"article": "Streicher, an associate professor of clinical obstetrics and gynecology at the Northwestern University Feinberg School of Medicine, said the study drew \"erroneous conclusions.\"\n(CNN) A new review of the \"little pink pill\" for women with low sexual desire says the drug doesn't work very well -- but some doctors and patients who've been using the treatment disagree.\nAccording to the FDA, which looked at three clinical trials of Addyi that included about 2,400 women, about 10% more patients treated with Addyi reported meaningful improvements in satisfying sexual events, sexual desire, or reduced distress compared to women taking a placebo.\n\"The data presented in this review suggests that the meaningful change caused by flibanserin is minimal,\" according to the team of Dutch researchers.\n\"We included all published and unpublished studies to capture a complete overview of the benefits and risks of flibanserin, without bias,\" Jaspers wrote in an email to CNN.\n", "question": "Does the story commit disease-mongering?", "explanation": "There are many who would say that HSDD is a construction by the pharmaceutical industry keen to capitalize off women\u2019s sexual health. \u00a0Whether you agree with that perspective or not, if you are writing about a controversial condition, you must include some coverage of that controversy, otherwise you are at risk of further medicalizing and hyping a condition that maybe doesn\u2019t, in most cases, warrant a medical treatment approach.", "answer": 0}, {"article": "The main limitation of the study is the underlying weakness of the studies evaluated.\n\u201cTo our knowledge, this is the first systematic review to assess complementary and alternative medicine for premature ejaculation.\u201d\n\nAccording to the International Society for Sexual Medicine, premature ejaculation can be a lifelong problem, and this primary form of the problem is usually defined as ejaculation happening within one minute of initiating vaginal intercourse every time a man has ever had sex.\nThe improvements were small, and the studies were of varying quality, but preliminary evidence suggests that acupuncture, Chinese herbal medicine, Ayurvedic herbal medicine and a Korean topical cream may all have desirable effects, researchers conclude in the journal Sexual Medicine.\n\u201cWe need treatments to address it, and it should be treated with equal seriousness as erectile dysfunction.\u201d\n\nThe prevalence of premature ejaculation is difficult to measure because of the differing definitions of the problem and some men\u2019s reluctance to report it.\n\u201cAlthough it is not openly discussed in the media - at least not as much as erectile problems have been discussed in the post-Viagra era - numerous studies report men feel frustrated, depressed and anxious because of this problem,\u201d said Ege Can Serefoglu of the Bagcilar Training and Research Hospital in Istanbul, Turkey.\n", "question": "Does the story commit disease-mongering?", "explanation": "Even though\u00a0the prevalence of premature ejaculation is a subject open to disease-mongering, this report did not veer in that direction, noting how difficult to measure it is. \u00a0\u201cSome studies suggest that between 20 and 30 percent of men report early ejaculation concerns, but the International Society for Sexual Medicine estimates that about 4 percent of men have a lifelong condition.\u201d", "answer": 1}, {"article": "However, based on some prior studies, independent experts say denosumab appears more effective at preventing spine fractures than three older pills \u2014 Fosamax, Actonel and Boniva \u2014 and calcitonin nasal sprays, which all use various pathways to slow down cells called osteoclasts that break down bone.\nSpine bone density loss was far smaller for those given the drug.\nThe two studies were released Tuesday by the New England Journal of Medicine.\nThey had 68 percent fewer spine fractures and 40 percent fewer hip fractures than the study participants who got dummy shots.\nThat's important because many patients stop taking other drugs due to side effects or frequent dosing.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story did not exaggerate the prevalence or seriousness of osteoporosis.\u00a0\u00a0 ", "answer": 1}, {"article": "An app called Natural Cycles has become the first to be classified as a medical device for use as contraception.\nAnd if the app gives you a \"red day\" \u2013 meaning you could be fertile \u2013 you have to abstain from sex, or use another method of protection such as condoms.\nEven so, the FPA advises that natural family planning is most effective if you\u2019re taught how to do it by a specialist teacher, and you monitor all three fertility indicators \u2013 temperature, menstrual cycle length, and cervical secretions.\nSo if you could reliably know when you've ovulated as a woman, and then you give that egg two or three days to die, any time after that in the cycle you will not get pregnant because there's no egg to fertilise,\" Dr Susan Walker, a senior lecturer in sexual health at Anglia Ruskin University, told BuzzFeed News.\n\"You really have to commit to it, whether you're doing it the traditional way or you're using an app.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering was evident in the article. It\u2019s quite clear that this is a device for use by women who do not want to get pregnant and while pregnancy is not a disease, an unwanted pregnancy is certainly a burden.", "answer": 1}, {"article": "Makers include General Electric Co\u2019s GE Healthcare Siemens AG, Toshiba Corp, Hitachi and Philips.\nIt is also possible the scans will turn up tumors that would never have killed the patients, and that some people will undergo unnecessary surgery if they are screened.\nIt is not clear when or how guidelines for lung cancer screening could be drawn up, and until they are, insurers including government programs such as Medicare are unlikely to pay the average $300 cost of a scan.\nThe study sponsored by the U.S. National Cancer Institute is the first to show that people can be screened for lung cancer, akin to mammograms for breast cancer and tests for colon and prostate cancer.\nFor the study, the middle-aged and elderly smokers were scanned with either a spiral CT or a chest X-ray once a year for three years starting in August 2002.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story avoided disease mongering and provided some great context. It says, for example, \u201cthe single best way to prevent lung cancer deaths is to never start smoking, and if already smoking, to quit permanently.\u201d It also says, \u201cAbout 10 percent of smokers develop lung cancer, but smoking causes other cancers as well as heart disease and stroke.\u201d", "answer": 1}, {"article": "THURSDAY, May 9, 2013 (HealthDay News) -- Scientists report positive results in early testing of a wireless pacemaker that's placed in the heart instead of being connected to it via wires from the upper chest.\n\"It is not known if it will be feasible to safely retrieve the old device.\nHe also has received stock options from the company.\n\"This is going to be the future,\" he said.\nFor more about pacemakers, visit the U.S. National Library of Medicine.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease-mongering in the story.", "answer": 1}, {"article": "Switching to AstraZeneca PLC's breast-cancer drug Arimidex after treatment with older drug tamoxifen not only helps women live longer, but also increases their chances of staying cancer-free after initial therapy for breast cancer, according to a study in the online edition of the Lancet Oncology medical journal.\n\nThe data, which come from more than 4,000 patients in three clinical trials, have shown that switching treatment from tamoxifen to Arimidex reduces the risk of dying by 29%.", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage is disease mongering. The story reports on a recent study relevant for women who have been diagnosed with early-stage breast cancer.", "answer": 1}, {"article": "\"Strikingly, these fasting-stimulated changes in the growth of vascular cells and subsequent immune alterations occur even after a single cycle of 24-hour fasting, and are completely reversed when mice start eating again,\" adds Yun Hye Kim.\nSuch fasting already shows benefits after only six weeks.\nThey exposed groups of mice to sixteen weeks of intermittent fasting.\nA type of white blood cell known to play a role in fighting inflammation is triggered.\nTheir glucose and insulin systems also remained more stable.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "A new study confirms that long-acting forms of contraception such as intrauterine devices and implants are better than birth control pills and patches at preventing pregnancies, giving doctors new ammunition to recommend these methods.\n\nThe study, to be published Thursday in the New England Journal of Medicine, involved about 7,500 women in a project promoting long-acting birth control to reduce unintended pregnancies. There are an estimated three million unplanned pregnancies a year in the U.S., often because of incorrect or...", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering at play here.", "answer": 1}, {"article": "What are the limitations of IVM?\nWith IVM, women undergo a shorter course\u2014 between 3 and 6 days\u2014 of hormones known as a \u201cpriming phase.\u201d\n\nOnce the eggs are retrieved, they\u2019re matured in a laboratory for approximately three days, fertilized and then implanted.\nWomen with polycystic ovary syndrome (PCOS) or who are at increased risk for ovarian hyperstimulation syndrome (OHSS)\u2014 which affects between 3 and 6 percent of women who go through IVF\u2014 may also benefit from IVM.\nAlthough IVF is still considered the gold standard, there\u2019s an infertility treatment available that is offering hope \u2014 in vitro maturation (IVM).\nAlthough IVM may eventually become more common, IVF still remains the standard of care and the most effective way for women to get pregnant.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article does a pretty good job of noting who is and is not a candidate for IVM. It could have done more to \u00a0give a broader picture of the rates of infertility among various groups of women in the U.S. It also could have noted that\u00a01-3% of all babies born in the U.S. are conceived with assisted reproductive technologies (IVF and its modifications).", "answer": 1}, {"article": "Eli Lilly announced promising data on its efforts to have its Cymbalta depression treatment also used as pain medicine, saying a study showed the drug \"significantly\" reduced chronic lower-back pain.\n\nLilly has been looking at the potential of Cymbalta for relieving the discomfort of fibromyalgia and osteoarthritis pain as well as back pain. The company's results of late have been boosted by the antidepressant, whose second-quarter sales jumped 26% to $654.4 million.", "question": "Does the story commit disease-mongering?", "explanation": "The story said that the drugmaker said \"a study showed the drug \u2018significantly\u2019 reduced chronic lower-back pain\" and that the company \"has been looking at the potential of Cymbalta for relieving the discomfort of fibromyalgia and osteoarthritis pain as well as back pain.\"\u00a0 The story never explained what \"chronic lower back pain\" meant in this study and therefore is too nonspecific with this often nonspecific diagnosis.\u00a0 Then, to let the company get away with the insinuation of progress against other conditions is unacceptable. ", "answer": 0}, {"article": "To learn more about the Society and the field of endocrinology, visit our site at http://www.\n\u2022 Smoking cessation, weight loss (if indicated), limiting or avoiding alcohol, maintaining adequate levels of vitamin D and calcium, eating a healthy diet, and regular physical activity are suggested for all women with prior breast cancer\n\u2022 Non-pharmacologic therapies for VMS such as cognitive behavioral therapy, hypnosis, and acupuncture may be helpful as are vaginal lubricants and moisturizers\n\u2022 Several emerging approaches such as selective estrogen receptor modulators (SERMs), Tissue selective estrogen complex (TSECs), estetrol, and neurokinin B inhibitors show promise as useful agents to expand options for symptom relief with less breast cancer risk but have not yet been tested to confirm safety in women with prior breast cancer\n\nOther authors of the study include: Cynthia A. Stuenkel of the University of California, San Diego in La Jolla, Calif.; Susan R. Davis of the School of Public Health and Preventative Medicine, Monash University in Australia; JoAnn V. Pinkerton of the University of Virginia in Charlottesville, Va.; Ann Gompel of Paris Descartes University in France; and Mary Ann Lumsden of the University of Glasgow School of Medicine, Dentistry, and Nursing in Scotland.\nMenopause is a normal part of a woman's aging process but pre-menopausal women treated with chemotherapy can also develop premature menopause, and consequently, severe menopausal symptoms including sleep disorders, vulvovaginal atrophy (VVA), vasomotor symptoms (VMS), mood changes, depressive symptoms, cardiovascular disease, osteopenia, and osteoporosis.\n\"Following breast cancer, women should generally not be treated with menopausal hormone therapy but should instead focus on lifestyle modifications such as smoking cessation, weight loss, and regular physical activity,\" said the study's first author, Richard J. Santen, M.D., of the University of Virginia Health System in Charlottesville, Va. \"Pharmacologic agents are also available to treat women with severe symptoms.\nThe study, \"Managing Menopausal Symptoms and Associated Clinical Issues in Breast Cancer Survivors\" is published online at https:/ , ahead of print.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The review did not commit disease mongering. However, by omitting the breakdown of breast cancer survivors by age the release might give the impression that chemotherapy-induced menopause symptoms are higher than they actually are. As noted above, the study states that 43 percent of these women are older than 65 at diagnosis and would not have chemotherapy induced menopausal symptoms.", "answer": 1}, {"article": "There\u2019s no cure for endometriosis.\n\u201cIt\u2019s a major advance,\u201d said Dr. Louis DePaolo, head of the fertility and infertility branch at the National Institute of Child Health and Human Development, \u201cand another option women have that\u2019s effective.\u201d\n\nNow the less good news: The drug won\u2019t cure endometriosis; it\u2019ll only tamp down the pain it causes.\nThe treatments available don\u2019t always help, and some have severe side effects\n\nWhen birth control pills or over-the-counter painkillers fail to help endometriosis pain, women are often left choosing between a monthly injection called Lupron Depot, which can put women into a profoundly menopausal state, or Danazol, a male hormone that often causes acne and facial hair growth.\nBut doctors have also found that the rate of retrograde menstruation is about the same in women with and without endometriosis, so they think additional factors spur the disorder in some.\n\u2022 Environmental factors: There\u2019s some evidence to suggest environmental exposures to certain chemicals may contribute to one\u2019s risk of developing endometriosis.\n", "question": "Does the story commit disease-mongering?", "explanation": "The reader will find ample information about the unpleasant symptoms of endometriosis. In some areas, it comes close to disease-mongering, when pointing out very rare instances of women needing many surgeries, or a case study of one woman having endometrial tissue in her nose. However, endometriosis is a medical condition, and often under-diagnosed, so we\u2019ll rate this satisfactory.", "answer": 1}, {"article": "Canha, who wasn\u2019t involved with this study, researches indoor air quality and sleep during different ventilation patterns.\nThe number of awakenings and sleep efficiency improved as carbon dioxide levels decreased.\nOn another night, the windows and door to the room were kept closed.\nOverall, skin temperature and the bed temperature were higher in closed conditions than open conditions.\nThey also wore a sensor that tracked their movements at night, including indications of restlessness.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "\"The study found an interesting protective association between low-dose aspirin and breast cancer,\" said lead author Christina A. Clarke, Ph.D., M.P.H., from the Cancer Prevention Institute of California.\nThis study differed from other studies that have looked at aspirin and cancer risk because it focused on the dose levels of the aspirin women had taken and tracked the frequency of the use of low-dose aspirin as opposed to regular aspirin.\nIn the ensuing years before 2013, 1,457 of these participants developed invasive breast cancer.\nIt was also able to look in detail at subtypes of breast cancer.\nOther collaborating authors include Alison J. Canchola, M.S., and Lisa M. Moy, M.P.H., from the Cancer Prevention Institute of California, and Susan L. Neuhausen, Ph.D., The Morris & Horowitz Families Professor in Cancer Etiology & Outcomes Research, Nadia T. Chung, M.P.H., and James V. Lacey Jr., Ph.D., M.P.H., from City of Hope.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here. The release mentions that HER2 negative is the most common type of breast cancer.", "answer": 1}, {"article": "Noctiva is also not recommended for the treatment of nocturia in pregnant women.\nBecause Noctiva is approved only for adults with nocturia caused by nocturnal polyuria, health care providers should confirm overproduction of urine at night with a 24-hour urine collection, if one has not been obtained previously.\n\u201cIt is important to know that Noctiva is not approved for all causes of night-time urination, so patients should discuss their symptoms with their health care provider who can determine the underlying cause of the night-time urination and whether Noctiva is right for them.\u201d\n\nNocturia (wakening at night to urinate) is a symptom that can be caused by a wide variety of conditions, such as congestive heart failure, poorly controlled diabetes mellitus, medications, or diseases of the bladder or prostate.\nAlthough there are other FDA-approved medications that also contain desmopressin, none of those medications are approved to treat nocturia.\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release doesn\u2019t engage in disease mongering. It provides useful context about what the condition is, but not how common it is. That would have been a useful addition.", "answer": 1}, {"article": "The college was launched in 2010, when the Florida Board of Governors made a landmark decision authorizing FAU to award the M.D.\nAccording to the U.S. Centers for Disease Control and Prevention, heart disease is the leading killer among men and women causing approximately 600,000 deaths each year.\nIn 2006, varenicline was approved as a safe and effective means to quit smoking and achieved permanent quit rates of approximately 25 percent.\nQuitting smoking significantly reduces risks of cardiovascular disease beginning within a matter of months and reaching the non-smoker status within a few years, even among older adults.\nPublic health efforts and effective cessation treatments including behavioral counseling and medication have resulted in a 14 percent decrease in smoking in the U.S. while the rates are markedly increasing in developing countries.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here, unless you count the unexplained nature of the \u201c17,000 premature deaths\u201d claim \u2014 which we already addressed under the section on benefits.", "answer": 1}, {"article": "Over the past 15 years, CHOP hematology researchers have performed clinical trials of gene therapy for hemophilia B that have helped define efficacy and dosing levels in humans.\nFemale patients may suffer excessive menstrual bleeding.\nThey are most commonly treated with regular infusions of clotting factor.\n\"We developed a unique animal model of this disease after identifying dogs with naturally occurring factor VII deficiency,\" said Margaritis.\nIn one dog, the effects persisted nearly three years.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering.", "answer": 1}, {"article": "While it\u2019s not entirely clear why, part of the reason may have to do with the fact that extreme exercise generates body heat, which can be detrimental to sperm health; for marathoners and people training at intense levels, finding ways to dissipate body heat is a major concern.\nAnother group did high intensity exercise on the treadmill but in short interval bouts.\nAbout one in three couples struggling with infertility can trace their issues to poor quality semen, and men are given all kinds of advice about ways to produce healthier sperm.\nCompared to the control group that didn\u2019t exercise, all of the men who followed a physical activity program showed improvements in a variety of measures of their sperm.\nThey wanted to see what effect different types of exercise, and different intensity activity, had on sperm quality and count.\n", "question": "Does the story commit disease-mongering?", "explanation": "No evidence of disease mongering here.", "answer": 1}, {"article": "In late July, Sen. David Vitter, R-Louisiana, wrote a letter to the FDA saying that there are no new safety concerns and that \"the [FDA advisory] committee's concerns appear to have been based on cost-effectiveness.\"\nThat's sad.\"\nPolicies get reviewed whenever there is additional information.\"\n\"Until just recently, I didn't know it was so precarious.\"\nSince then, it has also been approved as a treatment for certain types of lung, kidney and brain cancer.\n", "question": "Does the story commit disease-mongering?", "explanation": "", "answer": 1}, {"article": "Why Biogen is breathing a sigh of relief with the latest Alzheimer\u2019s data\n\nWe already know Eli Lilly\u2019s big bet on Alzheimer\u2019s disease didn\u2019t work. But a deep dive into just how it failed has provided a bit of encouragement to Biogen and the many companies still hoping to succeed where their rival fell short.\n\nLilly\u2019s treatment, solanezumab, had no significant effect on the buildup of toxic brain plaques believed by many to be responsible for Alzheimer\u2019s neuron-destroying effects. The company had already disclosed that the treatment failed to improve patients\u2019 cognition and function, but the new data, released Thursday night, shed some important light on the underlying biology.", "question": "Does the story commit disease-mongering?", "explanation": "No mongering here.", "answer": 1}, {"article": "Dr. P. Murali Doraiswamy, a biological psychiatrist at Duke who had helped recruit patients for the study, called the results among \u201c the most highly anticipated data from the entire meeting.\u201d\n\nTo compare the scans with autopsy results, the company scanned the brains of 35 people in hospices who were expected to die within six months.\nNeither the radiologists nor the pathologists knew whether the patients had dementia.\nSome had Alzheimer\u2019s and others did not.\nIn 34 of the 35 patients, the PET scan, the pathologists\u2019 report and the computerized pathology report agreed.\nPathologists in Montreal analyzed the brain slices with a computer that counted plaques.\n", "question": "Does the story commit disease-mongering?", "explanation": "\u00a0The story did not engage in disease mongering.", "answer": 1}, {"article": "Contact: Paul R. Sanberg at psanberg@health.usf.edu, Shinn-Zong Lin at shinnzong@yahoo.com.tw, or Associate Editor Samantha Portis at celltransplantation@gmail.com\n\"There are an increasing number of patients with advanced coronary artery disease that are not amenable to surgical or percutaneous revascularization,\" said study co-author Dr. Timothy D. Henry of the Cedars-Sinai Heart Institute.\n\"The results of our study are even more provocative given that the outcomes represent the effect of a single treatment,\" wrote the researchers.\n(June 1, 2016) - A two-year, multi-center clinical study with 167 patients with class III-IV refractory angina randomized to low and high dose CD34+ cells or placebo has revealed that patients who received either a high or low dose of CD34 -- a member of a family of proteins that have an impact on vascular-associated tissue -- cells had a significant reduction in angina frequency over patients who received placebo.\nIn addition, there was a significant reduction in the time to first hospitalization in cell-treated patients, with a trend toward reduction in mortality as well.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release never defines or describes angina at all. The release treats angina like a disease, rather than as a symptom of underlying health problems. That\u2019s problematic. We do not want to downplay the condition in any way, but it is important to distinguish between symptoms (such as significant chest pain) and underlying causes (such as reduced blood flow to the heart).", "answer": 0}, {"article": "So that was the only difference between the two diets, which then tells us that it's the avocado that has additional benefits which are beyond the unsaturated fat.\u201d\n\nThe findings are similar to a batch of studies that showed people who were given olive oil and nuts and told to add them to their diets ended up healthier.\nRepeated studies have shown it raises the risk of heart disease.\nThe lower fat diet provided 24 percent of calories from fat.\nThe Hass Avocado Board helped pay for the research, which was also funded by the U.S. government.\nThey were less likely to have strokes or heart attacks, and they were less likely to die over a period of years than people who didn\u2019t get the extra oils.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story didn\u2019t engage in disease mongering.", "answer": 1}, {"article": "CHICAGO (Reuters) - The longest-running breast cancer screening study ever conducted has shown that regular mammograms prevent deaths from breast cancer, and the number of lives saved increases over time, an international research team said on Tuesday.\nBut the latest results from the Swedish study show the rate of false positive results was low.\nThis will help for that,\u201d Destounis said.\nBreast cancer is the second-leading cause of cancer death among U.S. women, after lung cancer.\nIn the study, women were divided into two groups, one that received an invitation to have breast cancer screening and another that received usual care.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not exaggerate the prevalence or seriousness of breast cancer.\n", "answer": 1}, {"article": "ISI Group analyst Mark Schoenebaum said although the vemurafenib results look the most encouraging, the findings are unlikely to make a difference for current sales estimates, since virtually all eligible patients will be treated with both drugs, either in sequence or in combination.\nSide effects included skin rashes and joint pain.\nAbout half of all melanomas have the genetic aberration.\nYervoy works by spurring the immune system to fight off the cancer.\nAbout 18 percent of patients developed a low-grade skin cancer.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering of melanoma.", "answer": 1}, {"article": "Error code 404. Something went\n\nwrong and we can't seem to find\n\nthe page you're looking for.\n\n Report a broken link.", "question": "Does the story commit disease-mongering?", "explanation": "Not all people with lymphedema have symptoms as severe as the patient featured in this story, whose arm was \u201cpainfully swollen to lift anything heavy or even fit into her usual clothing.\u201d That should have been conveyed more clearly.\nThe story also quotes a surgeon saying that typical patients have \u201chad that swelling for a while\u201d and \u201ctreatment is an uphill battle.\u201d Of course, surgeons tend to see only a segment of cases that haven\u2019t responded well to other treatments.\nBreastcancer.org calls surgery \u201can option of last resort for severe lymphedema that does not respond to treatment. Most people with lymphedema would not be considered candidates for surgery.\u201d", "answer": 0}, {"article": "In this study, Lopez and colleagues tested the effects of agave fructans on bone growth in mice.\nTUESDAY, March 23, 2010 (HealthDay News) -- An ingredient in agave -- the plant used to make tequila -- may help fight bone-weakening osteoporosis and other diseases, Mexican researchers say.\n\"These results suggest that the supplementation of the standard diet with agave fructans prevented bone loss and improved bone formation, indicating the important role of agave fructans on the maintenance of healthy bone,\" Lopez said.\nPrevious research has also suggested that fructans stimulate the growth of beneficial bacteria in the large intestine in a way that increases the body's absorption of minerals, including calcium and magnesium, which are needed for bone growth.\n\"They can be used in many products for children and infants to help prevent various diseases, and can even be used in ice cream as a sugar substitute.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "Besides the headline claim about fighting bone loss, the story states that \"Experimental studies suggest that fructans may be beneficial in diabetes, obesity, stimulating the immune system of the body, decreasing levels of disease-causing bacteria in the intestine, relieving constipation and reducing the risk of colon cancer.\"\u00a0 Are you sure you didn\u2019t leave something out? ", "answer": 0}, {"article": "The study's primary endpoint was OS.\nThe technique uses an intricate network of magnets to aim a narrow proton beam at a tumor and \"paint\" the radiation dose onto it layer by layer.\nThey deposit the bulk of their cancer-fighting energy right at the tumor, thereby reducing the dose to cardiopulmonary structures, which impacts the toxicity, functional status, quality of life and even survival for patients, explained Chang.\nThe image quality was poor and didn't include a CT component in most facilities across the country,\" said Chang.\nThe study opened at MD Anderson in 2006; in this research, Chang and his colleague report on the study's five-year results.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in the release. Despite the favorable reporting of outcomes, most patients were dead at 5 years.", "answer": 1}, {"article": "\u201cFollowing a 'healthy diet' emerges as an important strategy for prevention of neurological disease, but remains to be proved.\u201d\n\nCathy A. Sila, MD, the George M. Humphrey II Professor of Neurology and the director of the Stroke & Cerebrovascular Center at the Neurological Institute Case Medical Center of Case Western Reserve University School of Medicine in Cleveland, Ohio, says the benefits of diet and lifestyle choices in disease prevention are more important than ever, given the rising costs of health care.\n\u201cNow, we see it may reduce stroke risk in people older than 65.\"\n\u201cWe do not know for sure, and we do not know which particular aspect of olive oil is the most relevant to stroke,\u201d he says.\n\u201cMaybe olive oil improves vascular risk factors such as hypertension, dyslipidemia, diabetes, heart disease, obesity, which may in turn reduce stroke risk, or it may be that olive oil is anti-inflammatory or an antioxidant.\u201d Scarmeas writes an accompanying editorial.\n\u201cOlive oil is a healthy fat and it can reduce cholesterol and inflammation, and has been shown to help reduce the incidence of heart disease,\u201d she says.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering of stroke in the story.", "answer": 1}, {"article": "The life-saving scans helped to spot those with heart disease so they could be given treatments to prevent heart attacks.\nThis involves inserting tubes into the body and heart to check the flow of blood and identify any obstructions that could pose a heart attack risk.\nThe number of patients undergoing additional procedures increased within the first year but had levelled out by the end of the five-year period.\nThe study had previously found that around a quarter of patients had their diagnoses reclassified after receiving the scan, prompting new treatments in many cases.\nThis is the first study to look at the impact of the scans on long-term survival rates.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering. Some information on the prevalence of heart attacks among the patient population would put the problem in context.", "answer": 2}, {"article": "gov.\nCAVEATS Most participants were white.\nMiddle-aged and older adults.\nMight fish consumption help the brain, too?\nExcept for trout, freshwater fish usually are lower in omega-3s.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering.", "answer": 1}, {"article": "In 37 years as a police officer, Edwin Michel coped with a plane crash, a sniper, wildfires and three bullet wounds.\n\nNothing much rattled him until he was diagnosed with prostate cancer in November 2016. His doctor said the cancer wouldn\u2019t kill him but Mr. Michel, now 76 years old, wasn\u2019t entirely reassured. He felt more confident after a genomics test later revealed his prostate cancer was very low risk. The test, known as Oncotype DX, takes a sample from a prostate biopsy and analyzes 17 genes in it to estimate how aggressive...", "question": "Does the story commit disease-mongering?", "explanation": "Men diagnosed with prostate cancer often have to make difficult treatment decisions that reconcile their fears of cancer progression against their fears of treatment complications.\u00a0 This story did a good job of pointing out the challenges here.", "answer": 1}, {"article": "In a prime time news conference, Obama said that doctors may think: \" 'You know what?\n\"It was becoming unacceptable to just take tonsils out because they were there or you had a few infections,\" says Richard Rosenfeld, an ear, nose and throat doctor at SUNY Downstate in Brooklyn, N.Y. \"People were growing up with their tonsils.\"\nWith sore throats, the ENTs recommend waiting (and treatment with antibiotics, if needed), unless a child has more than seven infections in a year.\nThe picture is further clouded because not all children with big tonsils have sleep-disordered breathing or frequent throat infections.\nDespite hundreds of studies, there's still surprisingly little research on whether tonsillectomy really helps reduce the risk of sore throats.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in overt disease-mongering. Good caveats that \u201cnot all children with big tonsils have sleep-disordered breathing or frequent throat infections. Because of that, in 2002 the American Academy of Pediatrics recommended that children have a sleep study before surgery is considered. About 530,000 tonsillectomies are performed in the United States each year.\u201d", "answer": 1}, {"article": "The U.S. Food and Drug Administration said Tuesday it has approved Cotellic, a drug produced by Swiss biotech company Roche, for use in combination with the vemurafenib medication as a treatment for advanced melanoma.\n\nThe drugs are intended to target the illness after it has spread to other parts of the body or can\u2019t be removed by surgery.", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering here.\u00a0 Advanced melanoma is a terrible disease and many treatments fail.", "answer": 1}, {"article": "Researchers studied 27 men, 21 years old and older.\nThe researchers reported their findings in the Dentistry article, \"Periodontal Treatment Improves Prostate Symptoms and Lowers Serum PSA in Men with High PSA and Chronic Periodontitis.\"\nThe men also had to have at least 18 teeth and were examined for signs of gum disease, such as increased levels of inflammation and bleeding and/or loose teeth due to attachment and bone loss.\nResearchers found 21 of the 27 participants had no or mild inflammation, but 15 had biopsy-confirmed malignancies.\nTreating gum disease reduced symptoms of prostate inflammation, called prostatitis, report researchers from Case Western Reserve University School of Dental Medicine and the Departments of Urology and Pathology at University Hospitals Case Medical Center.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release actually offers no incidence or prevalence data at all, and as a consequence, makes no overstatements about either gum disease or inflammatory disorders that are linked to it.", "answer": 1}, {"article": "A new asthma drug being developed by Sanofi and Regeneron Pharmaceuticals may help patients whose condition is not well controlled by existing medicines, according to the results of a small clinical trial released Tuesday.\n\nIn the 12-week study, the number of asthma attacks or other outbreaks of symptoms decreased by 87 percent in those getting the drug, dupilumab, compared with those getting a placebo.\n\nOther measures of lung function and disease control also improved, according to the study results, which were published online Tuesday in The New England Journal of Medicine and presented at the annual meeting of the American Thoracic Society in Philadelphia.\n\nDupilumab blocks the action of interleukin-4 and interleukin-13, two inflammatory chemicals made by the body that are believed to contribute to asthma. Sanofi and Regeneron say there are also preliminary signs dupilumab works against the skin condition atopic dermatitis, suggesting it can be blocking a biological pathway that contributes to multiple allergic conditions.", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering. Instead, it provides a nice description of asthma and the subset of asthma patients who are the target of this drug.", "answer": 1}, {"article": "Other researchers will be analyzing economic data.\nThey include people like Danielle Denlein, who, to her total shock, developed a serious heart problem.On October 20, 2008, at 1:50 p.m., Ms. Denlein was driving to a drug store to buy formula for her 5-day-old baby girl.\nThe hope is that the devices, now being tested in clinical trials, will save lives, reduce medical expenses and nudge heart patients toward managing their symptoms much the way people with diabetes manage theirs.\n\u201cThe plausible reason, we think, is that we got to these people much sooner in the course of their illness,\u201d Dr. Crossley said.\nThere are, for example, more than four million recordings of weights and blood pressures and over 60,000 instances when the defibrillators went off, shocking a patient\u2019s heart.\n", "question": "Does the story commit disease-mongering?", "explanation": "\u00a0The story opened with an anecdote that implied that something terrible was avoided.\u00a0 That, of course, is always hard to know. The punch line is that without the device reporting in to a clinician, the situation was one in which it \u00a0\"could have gone for months before the problem was discovered.\"\u00a0\u00a0 The story never considered the question of whether there is always value in immediate recognition of a situation.", "answer": 0}, {"article": "\"Cluster headache is a rare, debilitating and difficult to treat disorder with few effective acute therapies,\" Dr. Stephen Silberstein, director of the headache center at Jefferson University in Philadelphia, said in a statement.\nThere aren\u2019t many specific treatments but they include the migraine drug sumatriptan, delivered via auto-injector, and inhaled oxygen.\nThe device is a vagus nerve stimulator and it\u2019s not entirely clear how it works.\nSufferers can go months without an attack and then suffer several sudden headaches in a single day for days on end.\nThe idea is to disrupt signals that run along the vagus nerve, a giant nerve that runs from the brain all the way to the colon.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering about cluster headaches. The article provides context about the problem and how rare it is.", "answer": 1}, {"article": "There are plenty of questions left, said Dr. Ashesh Mehta, director of epilepsy surgery at the North Shore-LIJ Comprehensive Epilepsy Care Center in Great Neck, N.Y.\n\n\"This study is an important first step,\" said Mehta, who was not involved in the research.\nLearn more about epilepsy from the Epilepsy Foundation.\nTwo patients ultimately had the implants removed.\nSeveral of Cook's co-researchers work for the company.\nA device like this could help sort that out.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering of epileptic seizures.", "answer": 1}, {"article": "Dr Furyk's research was recently published in the Annals of Emergency Medicine: http://www.annemergmed.com/article/S0196-0644(16)30364-X/abstract\n\nAbout the Emergency Medicine Foundation - EMF is an Australasian non-profit organisation funds innovative, evidence-based emergency medicine research that will improve clinical practices to save lives, as well as deliver significant economic benefits to the healthcare system.\nThe Foundation was established in 2007 with the support of the Queensland Government.\nEMF runs two research grant programs - a national Rural and Remote program and a highly successful Queensland program - as well as a Research Support Network.\nWe're very excited because Tamsulosin treatment may also allow patients to be treated closer to home rather than needing referral to a major centre.\"\n\"This means patients with large stones might not need more complicated treatments including surgeries, and this has potential to improve care and reduce costs.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease-mongering here.", "answer": 1}, {"article": "Lung cancer is the No.\n\u201cThis new information adds to the growing body of evidence that metformin may help prevent and inhibit the progression of lung cancer,\u201d Gutterman said.\nPatients who had taken the drugs to control diabetes were much less likely to have lung cancer spread \u2014 which is when it becomes most deadly \u2014 the researchers told a meeting of the American College of Chest Physicians.\nIn April, researchers said a natural supplement derived from food, called myo-inositol, seems to stop the precancerous changes that lead to lung cancer.\nThose who had taken either a metformin drug or a TZD were significantly less likely to have advanced lung cancer that had spread \u2014 20 percent of those who took the drugs had tumors that had spread, versus 42 percent of those who had not.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article doesn\u2019t engage in disease-mongering regarding lung cancer and diabetes. We liked the caveat about the success of surgical removal of early-stage lung tumors.", "answer": 1}, {"article": "The study's authors acknowledged that their preliminary data offers \"promise for the use of time-restricted feeding as a weight loss technique in obese adults, but longer-term, large-scale randomized controlled trials [are needed].\"\n\"There are also many studies that either report no overall effect or sometimes the opposite.\nFurther research is now needed to uncover whether 16:8 works better than other fasting diets in terms of weight loss and health benefits.\nWe observed that fewer participants dropped out of this study when compared to studies on other fasting diets,\u201d said Varady.\nIndividuals who ate between 10 a.m. and 6 p.m. consumed around 350 fewer calories, resulting in a loss of 3 percent body weight, and their blood pressure dropped by around 7mm Hg.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering here.", "answer": 1}, {"article": "\"While reductions in [cardiovascular] death still trump these bleeding events, if rivaroxaban is approved, we should expect a number of bleeding events that will require medical attention,\" Hicks wrote.\nA final decision is expected by the end of June, according to the documents.\nOf those patients, 136 had bleeding in the brain.\nThe U.S. National Institute of Neurological Disorders and Stroke has more about stroke.\n\"Carefully selecting patients for rivaroxaban therapy will be necessary to mitigate these bleeding risks.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering.", "answer": 1}, {"article": "\"We think it will be a very important tool in the toolbag of surgeons and physicians treating obesity and its co-morbidities,\" said Gregory S. Lea, senior vice president and chief financial officer of EnteroMedics. \"When patients leave the diet, counseling and drug world and have nothing more, they turn to surgical procedures, and only 1% to 2% of patients who might be eligible for bariatric surgery are getting it.\"", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in fear-mongering.", "answer": 1}, {"article": "Sure enough, in the week when they ate eggs, volunteers had lower acylated ghrelin and higher PYY3-36 compared with the week when they ate cereal.\nNews flash: Eggs are really good for you.\nThis place conducts some serious research on diet and weight.\nAfter a two-week gap, the groups were switched.\nThey could have just asked people if they liked eating eggs for breakfast.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering.", "answer": 1}, {"article": "To learn more, visit njhealth.org.\n\"Ideally, we want to eliminate all staph aureus from the skin of eczema patients,\" said Leung.\n\"What the cream does is help the skin gain back its natural balance and create that barrier needed to keep it healthy.\"\nIt may seem strange to fight bacteria with more bacteria, but it could lead to a long-term solution for eczema patients\n\nEczema is the most common skin disease worldwide.\n\"He's little now, but dealing with eczema as a teen and an adult is really difficult,\" said Rodriguez.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering. Atopic dermatitis is very common and difficult to treat.", "answer": 1}, {"article": "Both methods have their limits and, \"while this study is very preliminary, if this radiotracer technology can prove to detect very early recurrence or metastasis in human patients, it could become extremely useful in either the pre- or post-treatment setting in selecting a treatment algorithm,\" Schwartz said.\nThe U.S. National Cancer Institute provides more information on prostate cancer.\nIf a specific change did not occur, that treatment could be abandoned and another tried instead.\nIf a treatment showed a marked change, it could continue to be used in that patient, hence \"personalized\" medicine.\n\"It also may help reduce the need for biopsy of possible metastatic lesions.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering.", "answer": 1}, {"article": "\u201cWhat does it mean, to improve metabolic health?\n\u201cWe are filling a space by combining natural compounds with scientific validation.\u201d\n\nThe active ingredients in Basis are nicotinamide riboside, a substance that makes NAD and is found in traces in many foods such as milk, and pterostilbene, an antioxidant found in blueberries.\nA leading biologist at the Massachusetts Institute of Technology, with backing from five scientists who are Nobel prize recipients, is wading into the murky world of dietary supplements with a new antiaging pill that is said to restore muscle tissue, improve brain function, and increase energy levels by improving \u201cmetabolic health.\u201d\n\nLeonard Guarente, one of the best-known antiaging researchers in the region, and the roster of eminent scientists have formed Elysium Health, which on Tuesday will debut its first product, a pill called Basis.\nMost of them have no scientific basis, and you don\u2019t know what you are getting.\u201d\n\nGuarente was involved in several other efforts to develop antiaging medicines that did not pan out.\nIf Elysium Health were developing Basis as a drug, it would have to conduct clinical trials with humans to prove that it works, and the Food and Drug Administration would have to sign off on its scientific evidence before it could be sold as medicine.\n", "question": "Does the story commit disease-mongering?", "explanation": "The premise of the new supplement \u2014 one that is never challenged by the story \u2014 is that aging is somehow a \u201ccondition\u201d that needs to be treated with a new medicine. Loss of muscle and other aspects of aging are normal changes that people experience as they age \u2014 not conditions in need of a cure. The framing of aging as a \u201ccondition\u201d opens the door to expensive and untested approaches that waste money and encourage the use of more pills that can interact unpredictably. The story should have done more to resist this framing.", "answer": 0}, {"article": "Actuarial five-year OS was 95.6 percent for the entire cohort.\nThe 2016 Annual Meeting is expected to attract more than 11,000 attendees from across the globe, including oncologists from all disciplines and members of the entire radiation oncology team.\nThe technique has become the standard of care for many non-surgical lung cancer patients, as it limits exposure to the heart and surrounding lungs.\nOur trial confirms that SBRT may be preferable to other treatment approaches for newly-diagnosed cases of prostate cancer, including more aggressive disease.\u201d\n\nThe abstract, \u201cFive-Year Outcomes from a Multi-Center Trial of Stereotactic Body Radiotherapy for Low- and Intermediate-Risk Prostate Cancer,\u201d will be presented in detail during a scientific session at ASTRO\u2019s 58th Annual Meeting at 7:45 a.m. Eastern time on Monday, September 26, 2016.\nABOUT ASTRO\u2019S ANNUAL MEETINGASTRO\u2019s 58th Annual Meeting, the nation\u2019s premier scientific meeting in radiation oncology, will be held September 25-28, 2016, at the Boston Convention and Exhibition Center in Boston.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release does not commit mongering. However, as noted above, the patients enrolled in the trial were a very low risk population and one could argue that some of these patients may not have needed treatment at all.", "answer": 1}, {"article": "The Site is down for maintenance.", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering of advanced breast cancer.", "answer": 1}, {"article": "In studies, clinically-tested, stimulant-free Capsimax was shown to significantly help improve body composition, promote thermogenesis and lipolysis, decrease appetite, accelerate metabolism and increase resting energy expenditure.\nThe study showed that supplementing with this low dose of Capsimax increased metabolic rate which calculated to an equivalent to burning an extra 116 calories per day.\nof fat lost over 30 days.\nThe company develops IP-protected, science-backed branded ingredients from natural sources using cutting edge technologies.\nWhether looking for a new ingredient to add to a finished product, or technology to enhance an existing ingredient, OmniActive delivers unmatched innovation.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering.", "answer": 1}, {"article": "The controls have had twice the death rate from aging-related diseases like heart failure and diabetes.\nHe called the results \"striking,\" even though the experiment was only a pilot study for a two-year trial of calorie restriction due to begin in the fall.\n\"There is no data on non-obese humans,\" said Eric Ravussin, chief of health and performance enhancement at the Pennington Biomedical Research Center at Louisiana State University.\n\"There's never been a study like this one,\" said Dr. Evan Hadley, director of geriatrics and clinical gerontology at the National Institute on Aging, which paid for the study.\nIt was probably preserved by evolution because it saved people from starving to death when food was scarce, but it is the bane of dieters because it means that the more weight they lose, the harder it is to keep reducing.\n", "question": "Does the story commit disease-mongering?", "explanation": "There isn\u2019t any discussion of how many Americans are overweight but not obese, so we can\u2019t judge the story unsatisfactory on this criterion. However, we are tempted to do so when the story states, without attribution or evidence to back it up: \u201cThe notion that going hungry could be the fountain of youth has captivated scientists and the public.\u201d ", "answer": 1}, {"article": "* Drug being developed by Pfizer, Elan and Johnson & Johnson\n\nLONDON, March 1 (Reuters) - New imaging technology suggests an experimental drug for Alzheimer\u2019s reduces clumps of plaque in the brain by around 25 percent, lifting hopes for a medicine that disappointed in clinical tests two years ago.\nThe treatment was generally well tolerated, although two patients on the highest dose had transient brain swelling.\nThe new study, which only involved 28 patients, is modest fillip.\nThe effect was similar with three different doses of the drug, they reported in the journal Lancet Neurology.\nBut a rival school blames toxic tangles caused by an abnormal build-up of the protein tau.\n", "question": "Does the story commit disease-mongering?", "explanation": "\u00a0The story did not engage in overt disease mongering.", "answer": 1}, {"article": "One was a low-fat diet that included lots of fruits, low-fat dairy, poultry, whole grains and small amounts of red meat.\nIt was also supported by a grant from the Hass Avocado Board, an industry group that the researchers say had no role in the design of the study or the interpretation of the data.\nThe only difference between the two was the avocado \u2014 the other diet had the same amount of fat from other sources.\nAnd given the reduction in funds available for research, it's become increasingly common for researchers to carry out these kinds of industry-supported studies.\nNew research finds that eating an avocado per day, as part of an overall diet rich in healthy fats, may help cut the bad kind cholesterol, known as LDL.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here. While LDL is termed the \u201cbad cholesterol\u201d without explanation, the story also doesn\u2019t equate high LDL cholesterol levels to disease or mortality.", "answer": 1}, {"article": "That\u2019s the most Mr. Skjoth will say about it.\n\u201cThere aren\u2019t a lot of options, and I\u2019d love to be able to say to my patients, \u2018This is something you can try that is worth the money.\u2019 But I can\u2019t do that yet.\u201d\n\nHarklinikken\u2019s formula, refined over 20 years, is derived from plants and cow\u2019s milk.\nBut during regular follow-up appointments, Harklinikken uses high-tech equipment to photograph and magnify the scalp and count new hairs and active follicles, which motivates users to adhere to the regimen.\nFor now, Maryanne Senna, a dermatologist and the director of the Hair Academic Innovative Research Unit at Massachusetts General Hospital in Boston, said the best she can tell patients who ask \u2014 and a lot of them do \u2014 is that Harklinikken won\u2019t do any harm.\nOne is how much emphasis the company places on compliance, the major stumbling block in the efficacy of any treatment, said Dr. Senna, an author of studies on the subject.\n", "question": "Does the story commit disease-mongering?", "explanation": "There\u2019s no disease mongering. However, we take issue with the use of the word \u201ccure\u201d in the headline because it\u2019s ill-defined; even the company says users achieve no more than 60 percent restoration of their lost hair. And it\u2019s debatable whether hair loss is a disease that needs to be cured. The story also plays into the firm\u2019s marketing mystique by calling the treatment \u201ca customized hair extract that\u2019s given only to those who pass a fairly rigorous selection process\u201d and saying it \u201cinspires great loyalty.\u201d", "answer": 1}, {"article": "\"We feel fatty-acid consumption exerts a beneficial effect on brain aging by promoting vascular health,\" said the study's lead author, Dr. Zaldy Tan, associate professor at the Easton Center for Alzheimer's Disease Research and the division of geriatrics at the University of California, Los Angeles.\nFind out more about brain health at the Alzheimer's Association.\nThis might include reducing blood pressure and inflammation, he added.\nAdults in the bottom 25 percent also tended to have smaller brain volume overall.\nThe participants were in the Framingham Offspring Study, which is predominately white.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "Neck pain was assessed by the Northwick Park Questionnaire (NPQ) at 3, 6, and 12 months.\nThe study is published in Annals of Internal Medicine.\nIn addition, persons with chronic neck pain often seek complimentary care to manage their condition, such as acupuncture or the Alexander Technique.\nOver time, both interventions resulted in a greater increase in self-efficacy than did usual care, and these improvements were associated with better NPQ outcomes.\nChronic neck pain is a leading cause of disability.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease-mongering here about\u00a0chronic neck pain.", "answer": 1}, {"article": "\"Brain signals change from day to day (even hour to hour), the signals may be different depending on context (am I trying to lift a full or an empty glass, do I watch someone draw or do I want to draw myself), and brain signals change while we learn a new task,\" he told BuzzFeed news.\nHe has some residual movement in his shoulders, and can use those working shoulder muscles to move his arms about.\nI was lucky to have friends with me who were able to pull me out of the water and get medical attention.\"\nOur understanding of how brain signals change will also be crucial to making this technology usable on a large scale.\nThat could come from better electrode designs or looking for different signals that are more stable.\n", "question": "Does the story commit disease-mongering?", "explanation": "Paralysis from spinal cord injuries is a devastating condition, so the story is not overstating the situation facing patients.", "answer": 1}, {"article": "Petersen and his team wanted to develop a test that any physician can administer to patients, without the need for any new technology or expensive equipment.\n\u201cBut what\u2019s nice about it is that it\u2019s a nice non-cognitive, motor factor so it\u2019s looking at another aspect of brain function.\u201d\n\nMORE: This Alzheimer\u2019s Breakthrough Could Be a Game Changer\n\nPetersen suggests that every physician should get this information on their patients at age 65; that way, they can have a baseline against which to compare any changes as their patients age.\n\u201cIf we had a simple blood test, a cholesterol test for Alzheimer\u2019s disease, that would help,\u201d says Dr. Ronald Petersen, director of the Alzheimer\u2019s Disease Research Center at the Mayo Clinic, \u201cbut we don\u2019t.\u201d But Petersen has a potential solution, and according to a new paper released Wednesday in the journal , his Alzheimer\u2019s test has promise.\nMORE: New Test May Predict Alzheimer\u2019s 10 Years Before Diagnosis\n\nWhile his test is a possible solution to that problem, he acknowledges that the results need be repeated before it\u2019s recommended on a wide scale to physicians across the country.\nCurrently, the only way to truly separate out those on the road to Alzheimer\u2019s is to conduct expensive imaging tests of the brain, or to do a spinal tap, an invasive procedure that extracts spinal fluid for signs of the amyloid protein that builds up in the disease.\n", "question": "Does the story commit disease-mongering?", "explanation": "While we give the story credit for not providing the reader with ominous statistics about the incidence of Alzheimer\u2019s or mild cognitive impairment, the suggestion that everyone over the age of 65 should have this testing certainly pings our scare-mongering radar. As does the story\u2019s inaccurate suggestion that a high score can help diagnose Alzheimer\u2019s disease, when it\u2019s really only indicative of mild cognitive impairment. As does the failure to put a \u201c7-fold increase in risk\u201d in the appropriate overall perspective, as discussed above under Benefits.", "answer": 0}, {"article": "If you can tolerate the side effects, I think many women will opt to take the extra years of letrozole, so this study is practice-changing.\u201d\n\nDr. J. Leonard Lichtenfeld, deputy chief medical officer for the American Cancer Society cautioned, however, that \u201cone has to be cautious in interpreting these results,\u201d partly because \u201cbased on what they show, there is no overall change in survival.\u201d\nThe study did not continue long enough to discover whether the lower risk of developing cancer in the opposite breast translated into a lower risk of death.\nThere was no difference in survival, however: 100 women in each group died during the study.\nLetrozole is available as a generic for less than $100 a month.\nIn a randomized controlled trial, 959 women were given the drug and 959 a placebo.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering in terms of the overall risk of developing breast cancer or the risk of recurrence.", "answer": 1}, {"article": "The trial was funded by Mayo Clinic.\nIn this group, the rate of heart attack, stroke and revascularization and death was 3.7 percent among those with a low ceramide score, but 16.4 percent in people with the highest ceramide levels.\nBut when researchers examined cardiovascular disease in this population by ceramide scores, people with the highest levels of ceramides were four times more likely to have an event compared with those with the lowest (7.8 vs. 2.2 percent, respectively).\nThe study found that individuals with the highest levels of blood ceramides were found to have a 3- to 4-times greater risk of having a cardiovascular event compared with those with the lowest ceramide score, regardless of their LDL cholesterol level or the presence of a blockage in the heart\u2019s arteries.\n\u201cOur research suggests that evaluating ceramide levels in patients who are not at immediate risk for coronary artery disease events may help cardiologists decide who could benefit from proactive and preventive treatment, such as statins, or lifestyle changes to prevent a serious cardiac event down the road,\u201d says Jeff Meeusen, Ph.D., a clinical chemist, co-director of Cardiovascular Laboratory Medicine at Mayo Clinic and the study\u2019s lead author.\n", "question": "Does the news release commit disease-mongering?", "explanation": "Heart disease is a serious and common problem. However, the news release skirts the line here by stating in the second paragraph that \u201cindividuals with the highest levels of blood ceramides were found to have a 3- to 4-times greater risk of having a cardiovascular event compared with those with the lowest ceramide score, regardless of their LDL cholesterol level or the presence of a blockage in the heart\u2019s arteries.\u201d Five paragraphs later, it provides the absolute risk information mentioned earlier. What\u2019s missing here are data explaining how heart disease risks for individuals with low LDL cholesterol, no blockages and high ceramide levels compare to the risks among individuals with high LDL cholesterol levels and/or evidence of heart artery blockage. Those numbers would\u2019ve helped put the \u201c3- to 4-times greater risk\u201d in context.", "answer": 1}, {"article": "\"Vitamin D supplementation trial in infancy: body composition effects at 3years of age in a prospective follow-up study from Montr\u00e9al\", by T. J. Hazell, S. Gallo, C. A. Vanstone, S. Agellon, C. Rodd, and H. A. Weiler, Pediatric Obesity doi:10.1111/ijpo.12105\nThis amount is in line with current Canadian health guidelines.\nThe additional benefit in terms of body composition came as a surprise for the research team.\nThe researchers found that higher doses did not provide any additional benefit -- at least not in terms of bone development.\nBut the body scans used to assess bone density also allowed the team to measure the children's muscle and fat mass.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release doesn\u2019t hype pediatric obesity.", "answer": 1}, {"article": "strongly supports the basic rationale being pursued at Sirtris, which focuses on the development of small-molecule compounds that directly activate the enzymatic activity of SIRT1 as a new therapeutic approach to many diseases of aging,\" Vlasuk wrote in an email to the journal.\nMitochondria provide the energy that cells need to function.\nThe study is in the May 1 issue of Cell Metabolism.\nThere was no effect on AMPK in mice given a lower dose of resveratrol.\nMice that have their SIRT1 gene deleted are born with developmental defects and are unsuitable for experiments, he explained.\n", "question": "Does the story commit disease-mongering?", "explanation": "Not applicable.\u00a0 Unless we\u2019re talking about aging in mice.", "answer": 2}, {"article": "Prescribing testosterone for age-related deficiency \u2014 which is only vaguely defined \u2014 took off in 2000. The trend was driven not by solid scientific evidence, but by the introduction of convenient, rub-on testosterone products, the first being Androgel. Many men are put on testosterone with no tests of their levels or despite tests showing normal levels, a study of Medicare claims found.", "question": "Does the story commit disease-mongering?", "explanation": "If anything this article is the opposite of disease mongering. It reports results of a study that was commissioned out of concern that testosterone is overprescribed to older men and that\u00a0many men\u00a0who use it either have normal testosterone levels have never been tested.\nOne minor\u00a0concern is that the context/fact-checking is delivered subtly and may be missed on a quick read.\nFor example:\nAbbVie, which donated its leading brand, Androgel, to the trials, said in a statement that the company is \u201ccommitted to our patients and is proud of our continuous support of research that advances science for the benefit of hypogonadism patients.\u201d\nAs explained elsewhere, hypogonadism occurs when the body doesn\u2019t produce enough of the hormone due to disease, injury, or chemotherapy.\u00a0\u00a0It\u2019s the condition for which testosterone-replacement therapy is approved\u2013not experimental use for mood, libido, low bone density, etc.", "answer": 1}, {"article": "However, Reid believes theirs is the first study to model the long-term effects of eating dark chocolate in reducing cardiovascular risk.\nReid and his team constructed a mathematical model to predict the long-term health effects of eating dark chocolate daily in high-risk people.\nThey did not study actual people eating actual chocolate.\nMaybe, according to a new study from Australia.\nSeveral studies have found that dark chocolate, with its heart-healthy flavonols, can lower blood pressure and improve cholesterol.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering of heart attack and stroke.", "answer": 1}, {"article": "Tens of thousands?\nThe way the study was done, he says, \"does not allow one to conclude\" that Provenge is working because it mobilizes the immune system specifically against prostate cancer.\nThe primary mystery is how Provenge extends life, since it doesn't shrink prostate tumors, as far as anyone can tell.\nAnd it's clear that experts are still scratching their heads about just how Provenge works.\n\"Prolongation of survival without a measurable antitumor effect is surprising,\" writes Dr. Dan Longo of the National Institute on Aging in a NEJM editorial.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering.\u00a0 The story makes it clear the drug was tested in men with prostate cancer who no longer respond to hormone therapy. ", "answer": 1}, {"article": "The therapy has even been featured on an episode of the TV series \u201cGrey\u2019s Anatomy.\u201d\n\nBut Dr. Ryan, a gastrointestinal oncologist, suggested in an interview that the procedure was being extended to because \u201cyou can\u2019t make a living doing this procedure in appendix cancer patients.\u201d\n\nHe debated the procedure publicly at the recent annual meeting of the American Society of Clinical Oncology.\nHe snipped those out and sewed up the wounds.\nHe then lifted the small intestine out of the body to sift it through his fingers.\nThe incision was sewn up around the tubes so the chemotherapy would not leak.\nMr. S. left the hospital eight days later, happy to have undergone the treatment.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering.", "answer": 1}, {"article": "He explained the results.\n\u2022 None New guidelines outline how to handle back pain \n\n\n\nIn the study, 320 adults with moderate to severe back pain received one of three approaches over 12 weeks:\n\u2022 Education about how to cope with back pain\n\n\n\nYoga was just as effective as physical therapy -- and both groups were about 20 percent less likely to use pain medication than patients receiving education alone.\nOpiate overdoses are now the leading cause of death for adults under age 50 -- an especially compelling reason to find approaches to chronic pain that don't involve narcotics.\n\"I feel, the more that one can do for one's self and not depend on medication, the healthier it is for your body,\" Zaborowski said.\n\"Yoga makes me think about my back and how I'm standing and if I'm standing properly, then I can function better.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering. But we thought the story tried too hard to raise the specter of opioid addiction, which was not the focus of the research itself. If you\u2019re going to go there, then at least go deeper into the topic of pain and addiction\u2013rather than just raising that scary reality and not explaining it better.", "answer": 1}, {"article": "Cancer experts said Tuesday that the actress and filmmaker Angelina Jolie Pitt was wise to have had her ovaries and fallopian tubes removed last week because she carries a genetic mutation, BRCA1, that significantly increases the risk of ovarian cancer, a disease so difficult to detect that it is often found only at an advanced, untreatable stage.\n\u201cProphylactic removal of ovaries and fallopian tubes is strongly recommended in women before age 40 in BRCA1 and BRCA2 mutation carriers,\u201d said Dr. Susan Domchek, executive director of the University of Pennsylvania\u2019s Basser Research Center, which specializes in BRCA mutations.\nIt is unclear how common the mutations are in other racial and ethnic groups.\nBRCA mutations cause about 5 to 10 percent of breast cancers and 10 to 15 percent of ovarian cancers among white women in the United States.\n\u201cThere is no effective screening for ovarian cancer and too many women with advanced stage ovarian cancer die of their disease.\u201d\n\nWriting for The New York Times\u2019s Op-Ed page, Ms. Jolie Pitt, 39, said she had expected to have her ovaries and fallopian tubes removed, a procedure called a laparoscopic bilateral salpingo-oophorectomy, but that a cancer scare made her decide to undergo the procedure sooner.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here. The story makes it clear that the BRCA 1 and BRCA 2 mutations are associated with a minority of cases of breast and ovarian cancer.", "answer": 1}, {"article": "Age-related macular degeneration (AMD) is a condition that affects older people.\nThe miniature telescope was developed by VisionCare Ophthalmic Technologies Inc. of Saratoga, Calif.\n\n\"This is truly a breakthrough technology for AMD patients as their treatment options have been limited until now,\" says Kathryn A. Colby, MD, PhD, an ophthalmic surgeon at the Massachusetts Eye and Ear Infirmary in Boston and an assistant professor of ophthalmology at Harvard Medical School.\nJuly 7, 2010 -- The FDA says it has approved the use of micro-sized implantable telescopes to improve vision in patients with end-stage, age-related macular degeneration.\n\"This innovation has the potential to provide many people with an improved quality of life,\" Jeffrey Shuren, MD, JD, director of the FDA's Center for Devices and Radiological Health, says in the news release.\nThe tiny device, called an Implantable Miniature Telescope (IMT), is designed to replace the natural lens.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was a form of disease-mongering in that the story gave the big picture of 8 million Americans with macular degeneration, 2 million of whom have had significant loss of vision.\u00a0 But the story didn\u2019t give an estimate of the number of people who might benefit from this approach \u2013 which is less than 8 million or less than 2 million.\u00a0 As the competing AP story explained, \"But it\u2019s only for a subset of the nearly 2 million Americans with advanced macular degeneration\u2026 Those 75 and older, with a certain degree of vision loss, who also need a cataract removed.\" So the 8 million figure is almost irrelevant in this discussion. ", "answer": 0}, {"article": "\"It's clear that these medications are beneficial,\" said Wadden, who has been a paid consultant to pharmaceutical companies as well as Weight Watchers. \"Unfortunately, there's a sense that they must not work if you have to take them indefinitely. But I think obesity medications should be used on a long-term basis for chronic weight management, just as I take a [cholesterol-lowering] statin and a blood-pressure medication for the long term.\"", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering in the piece. Instead, there was an explanation about the state of the obesity problem in the U.S. and the resulting health consequences.\nOn a related note, we must say that we would prefer that news outlets not use the term \u201cfat\u201d in referring to people who are overweight, which this story did. It has a pejorative sting to it that is no different than referring to kids who don\u2019t graduate from high school as \u201cdumb\u201d or people who suffer from alcoholism as \u201cdrunks.\u201d", "answer": 1}, {"article": "But this is not the case for those getting cortisone shots, he wrote; they \u201ctend to lag behind significantly at those time frames.\u201d In other words, in some way, the cortisone shots impede full recovery, and compared with those adopting a wait-and-see policy, those getting the shots \u201care worse off.\u201d Those people receiving multiple injections may be at particularly high risk for continuing damage.\nBut that cautionary experiment and others didn\u2019t slow the ascent of cortisone (also known as corticosteroids).\nThe injections seem to have \u201can effect on the neural receptors\u201d involved in creating the pain in the sore tendon, Dr. Khan said.\nSome people, including physicians, may decide that the answer remains yes.\nIt soon became a safe, reliable means to treat the pain and inflammation associated with sports injuries (as well as other conditions).\n", "question": "Does the story commit disease-mongering?", "explanation": "\nThere is no suggestion of disease-mongering in this article. These tendon problems are common and painful. They disrupt leisure-time activity and work.\n", "answer": 1}, {"article": "Correction: February 16, 2006, Thursday A front-page article on Feb. 8 about a new study finding that low-fat diets have no effect on the risk of cancer or heart disease misstated the incidence of breast cancer among women in the study.\n\"People are always thinking it's what they ate.\nNot everyone was convinced.\n(The difference was deemed statistically insignificant.)\nDr. Rossouw said the observational studies that led to the hypothesis about colon cancer and dietary fat included men and women.\n", "question": "Does the story commit disease-mongering?", "explanation": "", "answer": 1}, {"article": "Taking statins the day of a coronary artery bypass operation may significantly improve survival, a study in the Annals of Thoracic Surgery found.\nThe 1,788 who continued statins up to the day of surgery had a risk of death within 30 days of 1.7 percent, compared with 2.9 percent for 452 who stopped one to three days before surgery, and 3.8 percent for 781 who did not take statins or stopped more than 72 hours before their operations.\n\u201cWe already knew that people on statins before surgery had a decreased risk of death,\u201d said a co-author, Dr. Yi Deng, an assistant professor of anesthesiology at Baylor College of Medicine.\nAfter controlling for many preoperative health and behavioral characteristics, they found that compared with other patients, those who took statins on the day of surgery had a 48 percent reduced risk of dying in the next 30 days.\nResearchers looked at 3,021 heart surgery patients, most of whom were taking cholesterol-lowering statins.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering in the story. Heart surgery is a common procedure, and while generally also a safe one, it still carries risks, which is why this new data is relevant and interesting.", "answer": 1}, {"article": "Research presented at meetings should be considered preliminary until published in a peer-reviewed journal.\nThe potential for Clostridium novyi-NT to prompt an immune response against cancer is intriguing, said Sacha Gnjatic, who is associate director of the Human Immune Monitoring Center at Mount Sinai in New York City.\nResearchers have moved on to the next phase, in which patients taking the immunotherapy drug pembrolizumab (Keytruda) will also be treated with a single injection of Clostridium novyi-NT, Janku said.\nThe bacteria, Clostridium novyi-NT, can cause gas gangrene and sepsis if infection is allowed to run amok in a wound.\nIn 2000, the U.S. Centers for Disease Control and Prevention reported that a handful of drug users in the United Kingdom fell ill or died after their injection sites became infected with the bacteria.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease-mongering. It would have been helpful to discuss how many people have sarcomas, the type of cancer most patients in the trial had. According to the Sarcoma Alliance, there are about 15,000 new cases diagnosed annually in the U.S. There are also over 90,000 new cases of melanoma diagnosed annually.", "answer": 1}, {"article": "Lehnert presented the findings here at the annual meeting of the Radiological Society of North America.\nAbout another third reported less frequent episodes of low back pain, \"maybe once a day,\" says researcher Thomas Lehnert, MD, an assistant professor of radiology at Frankfurt University in Germany.\nThis condition occurs when the cushions, or discs, that serve as shock absorbers for the spine become inflamed and bulge or break open.\nIn the study, 119 people (37%) reported no pain at six months.\nPeople with this condition can experience pain, numbness, and weakness in the back, buttocks, and legs.\n", "question": "Does the story commit disease-mongering?", "explanation": "Though the story made the important point that the natural history of many disc herniations is to improve on their own with time, the story made an incorrect statement.\u00a0By saying that, \u201cAs\u00a0many as 80% of adults in the U.S. suffer from lower back pain at some point in their lives, and for many, the cause is a herniated disc,\u201d it implies incorrectly that disc herniations are a common cause of low back pain. It isn\u2019t. In fact, only a\u00a0small percent of patients with low back pain have a disc herniation as the cause. It is true that patients with pain radiating into the leg are more likely to have a disc herniation, but this was not stated and most patients with low back pain do not have associated leg pain.", "answer": 0}, {"article": "People with cluster headaches can have as many as eight per day in bouts that last for weeks or months.\nThe current treatment is injection with the drug sumatriptan, but frequent use of the drug isn't recommended because of the risk of adverse effects.\n\"To our knowledge, this is the first adequately powered trial of high-flow oxygen compared with placebo, and it confirms clinical experience and current guidelines that inhaled oxygen can be used as an acute attack therapy for episodic and chronic cluster headache,\" wrote Anna S. Cohen, of the National Hospital for Neurology and Neurosurgery in London, and colleagues.\nDuring four cluster headache episodes, the patients alternatively received high-flow oxygen (inhaled oxygen at 100 percent, 12 liters per minute, delivered by face mask, for 15 minutes at the start of the attack) or placebo (high-flow air).\n\"This work paves the way for further studies to optimize the administration of oxygen and its more widespread use as an acute attack treatment in cluster headache, offering an evidence-based alternative to those who cannot take triptan agents,\" they concluded.\n", "question": "Does the story commit disease-mongering?", "explanation": "There isn\u2019t any disease mongering in the story, but there also isn\u2019t any information provided about the prevalence of cluster headaches, nor of the proportion of all headaches that they represent.\u00a0 The reader therefore may have a hard time identifying the importance or applicability of this treatment.", "answer": 1}, {"article": "Two drugs once widely used to treat Parkinson's disease sharply increase the risk of heart-valve damage, researchers have found. The studies immediately prompted calls for the treatments to be discontinued or patients more closely monitored.\n\nPatients who take the drugs, pergolide or cabergoline, are four to seven times as likely to suffer damage to their heart valves as patients who don't take either one, according to two studies published in today's New England Journal of Medicine.", "question": "Does the story commit disease-mongering?", "explanation": "The news article misinterprets key data in the study about Parkinson\u2019s patients in the United Kingdom, thus highly inflating the occurrence of heart valve problems in patients taking the two Parkinson\u2019s drugs. In the UK cohort, 31 of 11,417 Parkinson\u2019s patients taking a variety of drugs developed heart valve disease. Of these 31 patients, 6 (19%) had taken the drug pergolide (brand name Permex), and another 6 (19%) had taken the drug cabergoline (Dostinex). However, the news story wrongly writes, \u201cIn one study in the United Kingdom, 19% of patients taking pergolide or cabergoline suffered heart-valve damage\u2026\u201d\u00a0 If that were the case, there would have been hundreds more cases than actually reported. According to the published study, 931 patients took pergolide and 1228 received cabergoline. The researchers concluded that if 10,000 patients took pergolide for one year, 30 would develop valve disease; if 10,000 took cabergoline for one year, 33 would develop valve disease. This amounts to a valve disease rate of about 0.3% per year per drug\u2014far fewer than was suggested by the news story. The article accurately notes that valve disease was five to seven times more likely to occur among the UK patients taking one of these two drugs, and similarly risky in the smaller, second study from Italy.", "answer": 0}, {"article": "Staying sexually active\u2014and considering sexuality an important part of life\u2014may be linked to higher cognitive functioning as people age, according to a study in the March issue of the American Journal of Geriatric Psychiatry.\n\nOlder men and women who were satisfied with their sexual relationships and considered sexuality an essential component of aging performed better on tests of cognitive function than those who felt sexuality and intimacy were unimportant, the research showed.", "question": "Does the story commit disease-mongering?", "explanation": "We didn\u2019t see any disease mongering.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Hormone replacement therapy (HRT) can carry serious health risks, but a new study adds to evidence that menopausal women who use the hormones may have lower odds of developing colon cancer.\nThese latest findings do not alter that advice.\nMost of the women were past menopause at the outset, and 61 percent were currently using HRT.\nThe implications of that finding, if any, are not yet clear.\nOver the next decade, 442 women were diagnosed with colon cancer.\n", "question": "Does the story commit disease-mongering?", "explanation": "Not a problem in this story. ", "answer": 1}, {"article": "The study, \"Pretreatment fasting plasma glucose and insulin modify dietary weight loss success: results from 3 randomized clinical trials,\" found that fasting blood sugar and/or fasting insulin can be used to select the optimal diet and to predict weight loss, particularly for people with prediabetes or diabetes.\n\"The beauty of this concept is its simplicity.\nApproximately one hundred different institutes, departments, laboratories, centres, museums, etc., form the nucleus of the University.\nThese diets could also be effective independent of caloric restriction.\nFor people with type 2 diabetes, the analysis found that a diet rich in healthy fats from plant sources would be effective for achieving weight loss.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering is evident in this release.", "answer": 1}, {"article": "Another benefit for this research was that \"this next generation test has the considerable advantage of not requiring baseline testing,\" said study co-author Carey Balaban, Ph.D., of the University of Pittsburgh.\nMild traumatic brain injury is typically diagnosed through physical exam findings.\nMild traumatic brain injury is a public health issue.\nIt's one of many developments that are needed to begin to curb the concussion epidemic.\"\nWith these findings, it appears the I-Portal goggle may be a solution.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in this news release.", "answer": 1}, {"article": "This is the main finding of a study conducted by a research partnership between Aarhus University, Aarhus University Hospital, the University of Southern Denmark and the University Medical Center Hamburg-Eppendorf, that has just been published in Multiple Sclerosis Journal.\n\u2022 The disease is found in both aggressive and more benign forms.\n\"Phasing out drugs in favour of training is not realistic.\n\u2022 There are about twice as many women as men with multiple sclerosis.\nThis aspect needs to be thoroughly explored,\" says Ulrik Dalgas.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in the news release.", "answer": 1}, {"article": "(Reuters Health) - When the results of a test wouldn\u2019t change how doctors manage a patient\u2019s care, most say it\u2019s not worth doing.\nAnd for many, family testing would be recommended for first-degree relatives, according to the report in JAMA Oncology.\n\u201cThe train has left the station and is unlikely to return,\u201d so it is important to assess how useful this additional testing can be, she concludes.\nThe researchers found that 40 women, or 4 percent of the total group, did have potentially harmful mutations in other genes.\n\u201cAre patients better off getting these much broader tests?\u201d he said.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering here. Breast cancer is a real concern to many women.", "answer": 1}, {"article": "WEDNESDAY, Nov. 28, 2012 (HealthDay News) -- Patients with rheumatoid arthritis are more likely to suffer hip dislocation after hip replacement surgery than those with osteoarthritis, a new study says.\nThe studies included arthritis patients aged 18 or older who had hip or knee replacements.\nFor the study, the investigators analyzed the findings of 40 studies published between January 1990 and December 2011.\nIn addition, rheumatoid arthritis patients have a higher infection risk after total knee replacement than osteoarthritis patients, the study authors found.\nThe study team found no differences between the two groups of arthritis patients in rates of follow-up surgery, or 90-day blood clot or death risk.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not inflate the number of people who might be appropriate candidates for joint replacement.", "answer": 1}, {"article": "\u201cThis study also has an important message for schools and the need to provide students with the opportunity to consume more fruits and vegetables as part of the school meal program.\u201d\n\nFarvid wasn\u2019t able to document a strong relationship between vegetables and lower breast cancer risk, but says that may be because the study wasn\u2019t powered enough to detect an effect.\nKale and oranges are high in vitamin C, another antioxidant.\nTaken together, the results show how critical diet can be in modulating risk of breast cancer.\nFruits and vegetables are staples in a healthy diet, and that includes one aimed at preventing cancer.\nThe added risk of cancer, however, was counterbalanced by a lower risk of heart disease.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "The prescription-free test is the first to report on three specific BRCA1 and BRCA2 breast cancer gene mutations, according to the FDA.\nThat accounts for a small percentage of people.\nThose most at risk of developing such cancers are of Eastern European Jewish descent.\nStill, the company, which already tests DNA for other health risks as well as ancestry, said this cancer test is \"a step in the right direction.\"\nBy analyzing DNA collected through a saliva sample, the test detects increased risk of developing breast, ovarian or prostate cancer.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "Organizers of the trial conceded that a major reason Lucentis was chosen was that Genentech, which is now owned by Roche, agreed to provide the drug free of charge and to contribute $9 million in additional financing \u2014 but only if Lucentis were used.\nThe fourth group got laser therapy plus a sham injection.\nRetinopathy results from damage to the blood vessels in the eye.\nLucentis is not approved as a treatment for macular edema.\nAnother got Lucentis, with laser therapy used only after six months and only if needed.\n", "question": "Does the story commit disease-mongering?", "explanation": "\u00a0The story did not engage in overt disease mongering.", "answer": 1}, {"article": "But are they benefiting from acupuncture itself, or just getting a placebo effect?\nBut that result has been called into question because the patients in the sham group probably figured out they were not getting the real thing.\nWhen the German researchers tracked how much pain medicine the patients used, they detected a noticeable difference between real acupuncture and the sham treatment.\n\u201cThe thing that can\u2019t be argued in my study is the duration of the effect.\nFor one thing, they note, patients in both groups received treatment with needles and electrical stimulation; the main difference was that in the sham group, the needles were not inserted as deeply and the stimulation was far shorter in duration.\n", "question": "Does the story commit disease-mongering?", "explanation": "      \n\n\n \n\n \nThe health conditions discussed in this article are vexing and real. There was no suggestion of disease mongering.\n\u00a0\n ", "answer": 1}, {"article": "The Ache: Common cholesterol-lowering drugs called statins can have unpleasant side effects, including muscle aches and weakness.\n\nThe Claim: An extract from a bitter, fragrant citrus fruit called bergamot, commonly known as a flavoring in Earl Grey tea, can lower cholesterol with minimal side effects, some scientists say. It also boosts good cholesterol, reduces fatty deposits in the liver and lowers blood sugar, they add.", "question": "Does the story commit disease-mongering?", "explanation": "This story does not hype the problem of high cholesterol or the association with heart disease, which is obviously among the most important causes of death in developed countries. But we do wish the story had made the link between cholesterol and heart disease more explicit.", "answer": 1}, {"article": "Sept. 17, 2010 -- The FDA has approved Krystexxa (pegloticase) for the treatment of gout.\nKrystexxa, which is made by Savient Pharmaceuticals Inc. of East Brunswick, N.J., is an enzyme that lowers uric acid levels by metabolizing it into a chemical that does not cause bodily damage and is then passed through the urine.\nThe drug is administered to patients every two weeks as an intravenous infusion.\nThe condition is associated with obesity, high blood pressure, high cholesterol, and diabetes.\nThe drug is associated with some serious side effects.\n", "question": "Does the story commit disease-mongering?", "explanation": "Story explains that \"about 3% of the 3 million adults with gout are not helped by conventional therapy.\"\u00a0 So no disease-mongering here. ", "answer": 1}, {"article": "Folic acid -- a synthetic version of folate found in many supplements and multivitamins -- has been shown to lower homocysteine in previous studies, but its effect on disease risk is disputed.\n\"A healthy diet likely remains important,\" Seshadri says.\n\"The role of supplementation remains unclear.\"\n\"Good nutrition should minimize the risk of Alzheimer's disease, but we can't say that any specific food has been proven to reduce this risk.\"\nHealth.com: 9 foods that may help save your memory\n\nOver the next seven years, 17 study participants were diagnosed with Alzheimer's disease.\n", "question": "Does the story commit disease-mongering?", "explanation": "", "answer": 2}, {"article": "\u201cNo one should die of hypertension.\nThe study also measured changes in risk scores of developing heart disease and stroke in the next 10 years, diastolic blood pressure, dietary changes, smoking cessation, cholesterol levels excluding the good cholesterol (HDL) and pulse pressure, which is the difference between the higher and lower (diastolic) numbers on the blood pressure reading.\nIn part, most of the studies here today show what to do \u2014 not how to achieve it,\u201d said Eric Peterson, a professor at Duke University School of Medicine and an associate editor of the Journal of the American Medical Association, during the conference.\nOver the 12 month period, systolic blood pressure of people in the Web-based lifestyle counseling group decreased by 10 mmHg, while it decreased by 6 mmHg for the other group.\nThe participants were divided into two groups, one of which received weekly emails with generic information about healthy living that is good for the heart and for reducing high blood pressure, and the other group received weekly emails with links to interactive tools and online multimedia, such as videos of people diagnosed with high blood pressure who made lifestyle changes.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does a good job of establishing how prevalent this condition is, and why new interventions are a good thing:\nHigh blood pressure affects 1 in every 3 adults in the United States, according to a fact sheet\u00a0by the Centers for Disease Control and Prevention. In 2013, high blood pressure was the major cause\u00a0behind 360,000 deaths in the United States. Reduction in high blood pressure has added health benefits because it can potentially reduce the likelihood of\u00a0heart attacks, strokes, chronic heart failure and kidney disease.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070715/23knee.htm was not found on this server.", "question": "Does the story commit disease-mongering?", "explanation": "\nPainful osteoarthritis is a debilitating disease for some and a nuisance for others. As the article notes, younger patients with arthritis are increasingly interested in a surgical remedy. But the article would have been more complete if it explained that arthritis does not always worsen or cripple its victims. Though there is limited evidence about what happens over time if people choose not to have surgery, one study found that after 10 to 18 years, about 4 out of 10 people stayed the same or had improved pain and mobility, while symptoms worsened in about 6 out of 10 (Clin. Orthop. Relat. Res. 1977;123:130-7.) By omitting this message (and other key information on risks, outcomes, and nonsurgical options), the story could lead readers to an overly rosy view of knee replacement.\u00a0 As written, the story implies that surgery is such a simple, effective, low-risk option that it should be performed in younger patients with less severe disease. \n", "answer": 0}, {"article": "Asked if the 34% improvement in cognitive decline is meaningful to a patient, Carrillo said, \"I have a family member with AD.\nThe drug is designed to prevent those clumps from forming.\nThe latest results come from a combined analysis of a 1,012-patient study and a 646-patient study, both of which involved people with mild to moderate Alzheimer's disease.\nI would be happy with a sustained cognitive benefit for my mother-in-law.\"\nThere was even a hint that the drug helped to slow the decline in functioning.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here. The story adequately described the type of person for which this research might be relevant.\n\u00a0", "answer": 1}, {"article": "\"The reason we're seeing these breakthroughs is because we did the basic science research to help us understand how this cancer happens, how it escapes therapy and how it progresses,\" Turnham says.\nAll improve survival by a few months.\nNone of the new drugs works for everyone.\nUntil recently, people with advanced melanoma often died within a year of diagnosis, even with chemotherapy.\nPatients with a limited time to live may not be so positive, Turnham says.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering in the story.", "answer": 1}, {"article": "Amid a growing body of evidence on the health impacts of the sport, the consensus aims to help current and would-be players maximise the health pros and minimise the health cons of golf, and to guide policy-makers and industry leaders on how best to make golf more inclusive and accessible and so encourage more people from all walks of life to take up the sport.\nThis can put people off, says the statement.\nAgreement was reached on 79 statements in three areas.\nGolf is sociable, and gets people outdoors, connecting with nature.\nMore people might be keen to take it up if golf were promoted as an enjoyable, lifelong outdoors activity that affords a sense of community and competitive challenge while providing some 'me time' as well as helping to fulfil recommended exercise quotas, says the statement.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering noted.", "answer": 1}, {"article": "When we\u2019re making choices in our 20s, we may think that a burger and fries is great, but the message is that there are alternatives that make a difference for the rest of your life.\nDuring the study the women experienced 405 heart attacks.\nThe benefits for the heart of eating strawberries and blueberries can build up over a lifetime, according to the latest research.\nBut women who consumed the most blueberries and strawberries had a 32% reduced risk of heart attack compared with the women who ate berries once a month or less.\nThey can also keep heart vessels more elastic and flexible, which helps combat the growth of plaques that can build up and rupture, causing heart attacks.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering.", "answer": 1}, {"article": "Plenary sessions feature the latest research on the use of and testing for cannabis, combating premature death due to preventable causes such as tobacco and alcohol, the development of an \"intelligent\" surgical knife, programmable bio-nano-chips, and the epigenetic causes of disease.\n\"This fast, accurate testing will allow doctors and patients to make more informed choices earlier to potentially slow the possible progress of Alzheimer's.\"\nResearchers from Randox Laboratories collaborated with research colleagues at the Medical University of Vienna and found that results from the two tests were in 100% agreement.\nAs biochip tests allow clinicians and researchers to quickly run multiple tests on one sample of blood, this new test is also faster and more affordable than the standard DNA test, producing results in only three hours.\n\"Pairing this test with medical and family history for risk of Alzheimer's disease has the real potential to advance personalized medicine,\" said Harte.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No mongering here.", "answer": 1}, {"article": "The result makes sense, since there's some previous evidence suggesting that higher-intensity exercise is tied to improving how the body processes sugar, said Neal Pire, an exercise physiologist who puts together medically based training programs at HNH Fitness in Oradell, N.J., a program of Holy Name Medical Center.\nThere weren't differences between the three groups.\n\"It doesn't take a lot,\" said Ross.\n\u2014 have no problem fitting regular aerobic exercise into their lives.\nA fourth group was told to do no exercise.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "\"For some women, it\u2019s biochemical or hormonal.\nIf it\u2019s hormonal, (flibanserin) isn\u2019t going to help, and if you\u2019re in a lousy relationship, it\u2019s not going to help that.\u2019\u2019\n\nThe issue of decreased desire affects marriages and a woman\u2019s self esteem, Goldstein and other experts said.\nThe issue of a woman\u2019s libido is more complicated than the dysfunction treated by the well-known little blue pill, according to women\u2019s sexual health experts.\nWomen who took the medicine, known as flibanserin, reported 22 percent more \"satisfying sexual events\" than those given a placebo in two clinical tests of 1,378 patients, according to abstracts released today at the European Society for Sexual Medicine annual meeting in Lyon, France.\nThe drug, which is being developed by the giant German drug maker Boehringer Ingelheim, could become the first treatment approved by U.S. regulators for women who suffer from hypoactive sexual desire disorder.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story misses the mark by failing to address the larger issue of whether acquired\u00a0hypoactive sexual desire disorder\u00a0in pre-menopausal women is a condition being promoted by pharmaceutical manufacturers to create a market for a new drug and to sell more drugs. Is interest in this drug based upon the hugely successful marketing of Viagra and other drugs for erectile dysfunction? \u00a0Instead of addressing these issues the story focuses on the potential benefits of flibanserin and relies mainly on interviews (See Evidence comments) to provide information.\u00a0 The story acknowledges that sexual desire, anxiety and satisfaction is multi-factorial and in many cases cannot be\u00a0helped by a pill.\u00a0However, commenting on the economic costs of divorce presumably attributed to a woman\u2019s low sexual desire blames women.\u00a0\u00a0", "answer": 0}, {"article": "If there really was such a big difference between the medications, why didn't it show up in these types of studies?\nThat inconsistency created a confusing split in the medical community.\nMost significantly, research showed a significant effect in reducing the risk of death with ACE inhibitors but not with ARBS.\nBut some doctors and researchers were puzzled by the fact that in head-to-head comparisons between the two classes of drugs they appeared to equally safe and effective.\nIf your risk is lower it's harder to show a benefit.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not appear to commit disease-mongering.", "answer": 1}, {"article": "\u201cThe question for me would be if there is a difference between patients who were treated with [both] immunotherapy [in the form of low doses of peanuts] and probiotics, and those who were treated with just immunotherapy.\u201d\n\nThat may have to wait for another study.\nFewer children in the treated group had an allergic reaction to the peanuts, and they also showed smaller reactions to skin prick tests with peanut allergen.\nCompared to 4% of children who didn\u2019t get any treatment, 82% of those receiving the combination therapy significantly reduced their allergic reactions to peanuts.\nThe Australian team added probiotics to further enhance the gut\u2019s ability to accept the peanuts and not trigger an immune reaction.\nBut it may be too early to call this a cure.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "It affects cells that play important roles in helping the immune system battle bacteria, viruses and fungi that can cause infections.\n\"Those stem cells are given back to the patient where they can go back to the bone marrow and make the blood cells for the rest of the patient's life,\" Kohn said.\n\"I had a baby to compare her to and I just knew, something was wrong with her,\" Vaccaro told CBS News.\nThe Vaccaros turned to Dr. Donald Kohn at the Broad Stem Cell Research Center at UCLA, where Kohn focuses on the development of new methods to treat genetic diseases of blood cells.\n\"We wore masks, we had hand sanitizer, we had raw hands from cleaning so much,\" Vaccaro recalled.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering is evident here. However, this\u00a0disease is serious and often fatal. There could have been more information provided such as the average life expectancy without treatment and with alternative treatments, to put the disease in context and not just say it is serious.", "answer": 1}, {"article": "The fact that recognizing and acknowledging a familiar person is such...\nA glimpse of Mom must first register on your occipital lobes as a pattern of light and shadow.\nIt's harder than you think to say hello to your mother--at least in terms of the work your brain has to do.\nYou must then summon the speech centers in your frontal lobes, which recruit your breath and muscles and at last allow you to utter the words Hi, Mom.\nFrom there it is relayed to your memory center, where it is identified by comparison with every other face you've ever seen.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in overt disease mongering.", "answer": 1}, {"article": "It updates a 1999 Cochrane review that found no strong evidence to recommend zinc as a help for colds.\n\u201cThe evidence from the recent trials does support the use of zinc lozenges in treatment of common cold,\u201d says study researcher Meenu Singh, MD, a pediatric pulmonologist at the Post Graduate Institute of Medical Research in Chandigarh, India.\n\u201cWe really don\u2019t have interventions for colds that work.\u201d\n\nThe review of 15 studies with 1,360 participants was published by the Cochrane group, an international collaboration of researchers that reviews evidence behind therapeutic interventions.\nThe review also found that zinc cut the number of days that kids missed school because of being sick and reduced the use of antibiotics by cold sufferers.\n\u201cThis is great news,\u201d says Kay Dickersin, PhD, an epidemiologist with the Johns Hopkins School of Public Health and director of the U.S. Cochrane Center.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering. We thought this story did a good job job explaining how zinc works to fight colds.\u00a0We recognize that the majority of readers are familiar with the common cold, but we would have liked to have seen some information on the estimated number of cases of the common cold, days out of work or other estimates to put the story into perspective.", "answer": 1}, {"article": "The other three people served as the control group.\nWEDNESDAY, Jan. 11, 2012 (HealthDay News) -- A new type of stem cell treatment for people with type 1 diabetes appears to help re-educate rogue immune system cells, which allows cells in the pancreas to start producing insulin again.\nThe treatment, which combines a patient's immune system cells with stem cells from a donor's cord blood, even worked in people with long-standing diabetes who were believed to have no insulin-producing ability.\n\"That means if you stop the autoimmune reaction, you may see beta cell regeneration, or there might be other precursor cells in the pancreas.\nThe concept is very intriguing, and the treatment seems to be so simple and so safe,\" said Dr. Luca Inverardi, deputy director of translational research at the Diabetes Research Institute, University of Miami School of Medicine.\n", "question": "Does the story commit disease-mongering?", "explanation": "We\u2019re going to rule this one Not Applicable.\nHere\u2019s the issue: While not the sort of disease-mongering we usually watch out for, this story leaves readers misinformed by failing to make clear that the patients in this experiment do not have the kind of diabetes that has dramatically increased along with the rise of obesity. This test included only people with the rarer form of diabetes (Type 1) in which patients don\u2019t produce enough insulin. The story should have noted that it is unknown whether this treatment strategy might offer any benefit for the millions of patients with Type 2 (also known as insulin-resistant) diabetes. Yes, the story says the patients in the trial had Type 1 diabetes, but most readers probably don\u2019t know that most people with diabetes have Type 2. The most important outcome measure of this trial was a reduction in insulin use, but only about a quarter of people with diabetes in the United States use insulin. (www.cdc.gov/diabetes/pubs/estimates11.htm) So readers are likely to have a greatly inflated sense of the number of people for whom this research is relevant.\nThis is a point to consider, but we won\u2019t rule it unsatisfactory because of it.\u00a0 For the same reason, though, we can\u2019t give it a satisfactory score.", "answer": 2}, {"article": "The essential tremor research has been supported by InSightec, the Focused Ultrasound Foundation and the BIRD (US-Israel Binational Industry Research and Development) Foundation.\nThe procedure is not for everyone with essential tremor.\nThe cost at UVA has not yet been determined.\nHigh-resolution images and video are available as well.\nThe remaining 25 percent underwent a sham procedure, to act as the control group.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release does not appear to disease-monger.", "answer": 1}, {"article": "Medtronic Inc. and Eli Lilly & Co. agreed to collaborate on an early stage research project for a potential Parkinson's-disease treatment that involves delivering medication directly to the brain\u2014a goal that has long eluded drug makers.\n\nThe pact, announced Tuesday, adds to Medtronic's roster of projects aimed at using implantable drug pumps and catheters to circumvent the blood-brain barrier. The tightly packed network of cells in brain capillaries only lets certain substances through, such as key nutrients, making brain-based...", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease-mongering in the story.", "answer": 1}, {"article": "MONDAY, Jan. 12, 2015 (HealthDay News) -- Higher vitamin D levels in patients with advanced colon cancer appear to improve response to chemotherapy and targeted anti-cancer drugs, researchers say.\nIt also took longer for cancer to progress in people with higher vitamin D levels -- an average 12.2 months compared with about 10 months in the group with the lowest.\nAfter adjusting for prognosis and healthy behaviors, the researchers found that patients in the group with the highest levels of vitamin D lived about eight months longer on average than those in the group with the lowest levels.\nThis increase in progression-free survival is the most compelling evidence indicating that vitamin D makes a difference in colon cancer, said Dr. Smitha Krishnamurthi, an associate professor of hematology and oncology at Case Western Reserve University School of Medicine in Cleveland.\nThose patients survived one-third longer than patients with low levels of vitamin D -- an average 32.6 months, compared with 24.5 months, the researchers found.\n", "question": "Does the story commit disease-mongering?", "explanation": "Metastatic colorectal cancer is life altering and life threatening at the time of diagnosis. It doesn\u2019t get more serious than that. No mongering here.", "answer": 1}, {"article": "The scientists, writing online on Oct. 4 in The New England Journal of Medicine, found that both treatments significantly reduced incontinence episodes.\nBotox injections are also used, often in cases where the medicine does not work.\nThe most common treatment for urinary incontinence is a daily dose of an anticholinergic medicine that alters the action of certain nerves.\nDry mouth was much more common in those who took the medicine; urinary infections and incomplete emptying of the bladder were more common in those given Botox.\n\u201cThis gives patients the information to make an informed decision.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering.", "answer": 1}, {"article": "\"Great.\n\"So before we activated the device, we have all sorts of problems\u2026 This is basically your brain saying, 'I'm not breathing.'\nFor years, all Siravo and her husband, David, wanted was a good night's rest \u2013 and now they're finally getting it.\nAn estimated 22 million Americans suffer from sleep apnea, putting them at greater risk for diabetes, heart disease, stroke and memory loss.\nExhausted, the 59-year-old could barely do her job as a nurse \u2013 and she knew something wasn't right.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story only includes the perspective of one patient with very severe sleep apnea, but never clarifies how many people with sleep apnea have mild, moderate or severe sleep apnea. We\u2019re left to assume it\u2019s a whole heck of a lot of people, because the story says this new treatment \u201cis offering hope for millions of patients.\u201d This lack of clarity adds up to disease-mongering.", "answer": 0}, {"article": "Sandoval is alive today because of an experimental form of immunotherapy called CAR-T.\nOn Friday, Moffitt Cancer Center and MD Anderson reported test results of 101 patients with advanced lymphoma who had failed previous therapy and were treated with CAR-T.\n\n\u201cIt puts a GPS navigation on the front of the cell so that when they\u2019re infused back in they know where to go and kill the lymphoma,\u201d said Dr. Frederick Locke, who helped lead the trial.\nWith CAR-T, a patient\u2019s own immune cells are removed from the body, reprogrammed to find and destroy cancer cells, then put back into the bloodstream.\nThe FDA will review these results and could make a decision on approval by the end of the year.\nNormally, our immune cells are good at killing invaders like bacteria but bad at fighting cancer.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story reports that the trial included patients with \u201cadvanced lymphoma who had failed previous therapy.\u201d\nHowever, the lack of detail could lead many readers to believe it applies to more lymphoma patients than just the B-cell non-Hodgkin lymphoma patients who had already undergone multiple prior treatment attempts.", "answer": 1}, {"article": "Severely premature babies are more likely to live if they receive intensive-care treatments rather than palliative care to keep them comfortable, according to a U.S. government-funded study published Thursday.\n\nWhether babies born at the extreme edge of viability, generally considered to be 22, 23 or 24 weeks of gestation, should be aggressively medically treated is a controversial issue among pediatric experts. These infants often don\u2019t survive and, even if they do, many have substantial long-term health problems.", "question": "Does the story commit disease-mongering?", "explanation": "The piece does not engage in disease mongering.", "answer": 1}, {"article": "Yet Williams hopes that the more supportive and positive communication patterns that many of the caregivers showed will help nurses coach spouses and family members affected by Alzheimer\u2019s.\nPrevious research has found that communication decline among people with dementia is a significant source of stress to caregivers, and most say they need education about communication.\nThe couples, who were recruited from a day program for people with memory disorders and their spouses, were receiving coaching in communication, with caregivers learning to listen, to avoid arguing, to not treat their spouse like a child.\nThe caregiving spouses seemed to value their partners\u2019 efforts to communicate as much as or more than the actual content of their conversations.\nA new study identifies patterns of communication that can help couples affected by Alzheimer\u2019s maintain a sense of connection, which could improve quality of life for both partners.\n", "question": "Does the story commit disease-mongering?", "explanation": "While Alzheimer\u2019s disease does carry some fear aspect among the public, this story does not seem to play on that fear but instead offers constructive ideas for maintaining communications within couples where one person has Alzheimer\u2019s. The statistics offered in the story seem to line up with those presented in this NIH fact sheet.", "answer": 1}, {"article": "\u2022 This is the first time tandospirone has be shown to reverse the deficit in brain neurogenesis induced by heavy alcohol consumption\n\u2022 The researchers also showed in mice that the drug was effective in stopping anxiety-like behaviours associated with alcohol withdrawal, and this was accompanied by a significant decrease in binge-like alcohol intake\n\n\"This is a novel discovery that tandospirone can reverse the deficit in neurogenesis caused by alcohol,\" said study leader neuroscientist Professor Selena Bartlett from QUT's Institute of Health and Biomedical Innovation.\nThe findings have been published in Scientific Reports.\nIt is commonly used there and shown to be highly effective in treating general anxiety and well tolerated with limited adverse effects.\"\n\"This drug is relatively new and available only in China and Japan.\n\"This is not just another drug that shows promise in helping to reduce binge drinking,\" she said.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release does not appear to commit disease mongering.", "answer": 1}, {"article": "Tomei, a self-proclaimed animal lover, expressed that the effort is close to her heart.\nSometimes, individuals with CDE have trouble opening their eyes, but Tomei said she went to the doctor and reported mild but incessant itchiness and dryness, and was diagnosed with CDE.\nActress Marisa Tomei is one of among an estimated 5 million Americans who suffers from chronic dry eye (CDE), a condition that can cause symptoms such as itchiness, stinging, difficulty making tears and blurred vision.\nIf you think you may be suffering from CDE, Tomei advised visiting your doctor to receive a diagnosis.\n\u201cIt was as simple as going to the doctor, getting a prescription and trying RESTASIS\u00ae,\u201d Tomei, 51, who stars in the upcoming \u201cSpider-Man: Homecoming\u201d movie, told FoxNews.com.\n", "question": "Does the story commit disease-mongering?", "explanation": "This is pretty clearly as over-the-top\u00a0disease mongering as you\u2019ll find, and the helpful-sounding self-diagnostic questionnaire is a\u00a0huge red flag indicating that people are about to be turned into patients. Also, turning chronic dry eye into an acronym\u2013\u201cCDE\u201d\u2013elevates it to\u00a0medical jargon status.", "answer": 0}, {"article": "Which sounds worse to you?\nThe study, published in the Pediatric Infectious Disease Journal, looked at the published data about effects from the vaccine and found that it has a \u201cfavorable safety profile.\u201d This study comes after many other previous studies that show essentially the same thing.\nThere is no correlation between getting the Gardasil vaccine and seriously adverse effects such as \u201cautoimmune diseases (including Guillain-Barre Syndrome and multiple sclerosis), anaphylaxis, venous thromboembolism, and stroke.\u201d\n\nMind you, all these things and more have been used by people who attack vaccines as an argument against it.\nEven more frustrating about this vaccine is that it\u2019s being fought by an unusual group of people; while most anti-vax leanings are not affiliated with any particular political persuasion, Gardasil gets attacked additionally by conservatives who think that girls getting it will become more promiscuous, because HPV is a sexually transmitted disease.\nThe Gardasil vaccine, on the other hand, caused some people to faint after getting it, and others got mild skin infections\u2014both of which occur somewhat rarely with other vaccines too, as you might expect.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story\u2019s assertion that cervical cancer causes 4,000 deaths each year in the United States is backed up by the Centers for Disease Control and Prevention. But that number doesn\u2019t really give much sense of one\u2019s overall lifetime risk of developing the disease and whether the disease is common or relatively rare. It would have been useful to know, comparatively, how common cervical cancer is and how it ranks in relation to other cancers.", "answer": 1}, {"article": "And while the percentage of American adults who smoke is at the lowest level since the CDC began tracking such data, there are still an estimated 40 million adult smokers in the U.S.\nWith a year-round campaign we could save even more lives and money.\u201d\n\nTips, the first federally funded anti-smoking paid media campaign, features former smokers talking about their smoking-related illnesses.\n\u201cThe money spent in one year on Tips is less than the amount the tobacco industry spends on advertising and promotion in just 3 days.\u201d\n\nThe most recent Surgeon General\u2019s Report, The Health Consequences of Smoking\u201450 Years of Progress, called for airing effective messages such as the Tips ads with high frequency and exposure for 12 months a year for a decade or more.\n\u201cThe Tips campaign is an important counter measure to the $1 million that the tobacco industry spends each hour on cigarette advertising and promotion,\u201d said Corinne Graffunder, Dr.P.H., director of CDC\u2019s Office on Smoking and Health.\nUnlike the 2012 campaign, which aired for 12 consecutive weeks, the 2014 campaign aired in two phases, from February 3 to April 6 and from July 7 to September 7.\n", "question": "Does the news release commit disease-mongering?", "explanation": "Normally, we ding releases or news stories that equate risk factors and health effects. There is, after all, a significant difference between the two. This release emphasizes the costs \u2014 both human and economic \u2014 of smoking, to the point of disease mongering. However, given the overwhelming abundance of research linking cigarette smoking to a wide array of severe health problems, we think this may be the exception to the rule. What keeps it on the satisfactory side is the language in the release highlighting smoking as a risk factor to cancer, stroke and other health problems.", "answer": 1}, {"article": "In dark suits and blue shirts, with serious expressions on their round faces, they walked to stand next to their mother in a very beige room outside Washington, D.C.\nRowan\u2019s gait seems better.\nHis 12th birthday is in early November.\nHe uses an electric mobility scooter for long distances, but he can still walk.\nSomeday, they will not be able to walk.\n", "question": "Does the story commit disease-mongering?", "explanation": "Duchenne muscular dystrophy is a killer.", "answer": 1}, {"article": "Bone-health experts are making a new push to reduce rates of osteoporosis, with a particular focus on controlling the bone-wasting disease in men.\n\nAn important goal is to get greater numbers of men to be tested for osteoporosis when they come to a hospital or clinic with a fracture to the wrist, vertebrae or other bones that wasn\u2019t from a major accident or trauma. Doctors call this a fragility fracture\u2014one that results from a decrease in bone density.", "question": "Does the story commit disease-mongering?", "explanation": "There\u2019s no disease mongering in the story. Instead, it provides some nice descriptions of bone health and bone health measurement to help put osteoporosis in context. \u201cBone tissue is always breaking down. When it isn\u2019t replaced fast enough, bones become less dense and prone to breakage, even with a relatively minor fall or bump. Tests for osteoporosis include a bone-density scan, a type of X-ray of the hip, wrist or spine, and blood or urine tests to check calcium and vitamin D levels.\u201d\nTo earn extra points here, the authors could have stated that screening asymptomatic older men for bone density, similar to women, is controversial. However, for individuals who have already had a fracture that may be due to osteoporosis, experts suggest that screening both men and women is warranted \u2014 although the data supporting this only comes from studies involving women.", "answer": 1}, {"article": "Toenail fungus causes nails to become thick, yellow and brittle in a way that looks pretty ugly and can be painful.\nCompared with oral medication, he says, \u201cthe odds of success are better with the laser; plus, there\u2019s no side effects.\u201d\n\nThe most common oral treatment, Lamisil, works for about two out of three patients, according to Lamisil\u2019s FDA-approved prescribing information, but it has been associated with rare cases of serious liver problems.\n\u201cI\u2019ve had patients come in who have had laser procedures and not seen long-term success.\u201d\n\nFirestone also says that over-the-counter antifungal nail creams and ointments rarely work because they can\u2019t penetrate the nail root.\nIn this case, there is a chance.\u201d\n\nEven John Strisower, the founder of PinPointe USA, says patients should expect at least a minimal reinfection within five years after laser treatment.\nIn one small study about laser treatment for toenail fungus, which appeared last year in the Journal of the American Podiatric Medical Association, \u201c26 eligible toes (ten mild, seven moderate, and nine severe)\u201d were treated with a laser produced by Nomir Medical Technologies, which is still seeking FDA approval.\n", "question": "Does the story commit disease-mongering?", "explanation": "This is where the story really sunk low. It frames the story like \u201cJaws\u201d for people with funky feet.\n\u201cFor people with toenail fungus, there is no good time to wear sandals. Not even at the beach in July. Toenail fungus causes nails to become thick, yellow and brittle in a way that looks pretty ugly and can be painful.\u201d\nWe can just see the readers reaching for their shoes as they\u00a0read that lead. No way are they going to the beach after reading this. It\u00a0gets worse, though.\n\u201cSufferers can spend years and hundreds of dollars trying to clear the infection with drugs, topical treatments and home remedies, sometimes to no avail.\u201d\nWhen will the agony\u00a0end, the readers ask themselves.\u00a0Cue the dramatic music, as Washington podiatrist Stephen J. Kominsky leaps up out of the page\u00a0to say:\u00a0\u201cThe problem is huge. It is bigger than you can imagine. \u2026I would say 70 percent of the patients who come into my office have fungal infections on their toenails.\u201d\nKominsky goes unchallenged for most of the article, despite his apparent lack of\u00a0documented proof for any of his statements and\u00a0the fact that he has every incentive to want to sell these treatments to the feet shy masses.\nFinally, profiling one patient who \u201cdid not want his full name associated with toenail fungus\u201d paints this as a scourge of society.\nThis is some pretty classic disease-mongering at play.", "answer": 0}, {"article": "\"The consistency among the results lead to the unequivocal conclusion that there is no clinical benefit of the use of folic acid and vitamin B12 (with or without the addition of vitamin B6) in patients\" with heart disease, wrote Joseph Loscalzo of the Brigham and Women's Hospital in Boston in an editorial that will be published with the studies.\n\"The homocysteine theory really isn't getting much attention anymore,\" he said.\n\"There are hundreds, if not thousands, of papers showing that.\"\nKilmer McCully of the V.A.\nPrevious research had indicated people with high homocysteine levels were at greater risk.\n", "question": "Does the story commit disease-mongering?", "explanation": "", "answer": 1}, {"article": "What causes the disc to herniate in the first place?\nIn an effort to determine which approach is best, Dr. Weinstein's launched a major study of over 1,200 patients with back pain.\nIf you get a tear in your tire, or your car, you would get a bulge,\" Dr. Weinstein explains.\nThe herniated disc, or bulge, can press on the nerves in the spine, causing pain.\nI would go in the yard, spend five minutes in the yard raking leaves and have to sit down or lay down,\" Noah says.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story crosses the line into disease mongering in the beginning of the story by stating that back pain is \"almost as common as the common cold.\" Although back pain is common, this story is really about herniated disc, a specific back condition that is relatively uncommon. The story does not clearly differentiate between the average patient with low back pain and the patients enrolled in this study who had sciatica due to a herniated disc. The study goes on to describe what a herniated disc is, but the first paragraph implies that 4 out of 5 of us will have the condition described in the story.", "answer": 0}, {"article": "But there is debate about whether the eye movement makes a difference, said Stephen Holland, founder of the Capital Institute for Cognitive Therapy and co-author of the textbook \u201cTreatment Plans and Interventions for Depression and Anxiety Disorders.\u201d \u201cThe question is whether stimulation adds to it.\u201d He does not use it in his practice because he considers it no more effective than cognitive behavioral therapy.\nThey describe the memories to the therapist, who gives guidance as needed.\nMemories formed under the adrenaline of trauma are never put to rest, she said.\n\u201cIt\u2019s integrating what\u2019s stuck in time,\u201d explained Kalin, the psychologist.\nWhat are we doing?\u201d\n\nBut Henn was encouraged by the progress she made.\n", "question": "Does the story commit disease-mongering?", "explanation": "PTSD is a legitimate health issue that is difficult to treat. No disease mongering.", "answer": 1}, {"article": "The U.S. Food and Drug Administration today approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis).\nThe most common side effects include injection site reactions; cold sores in the mouth or on the lips; and eye and eyelid inflammation, including redness, swelling and itching.\nOverall, participants who received Dupixent achieved greater response, defined as clear or almost clear skin, and experienced a reduction in itch after 16 weeks of treatment.\nThe safety and efficacy of Dupixent have not been established in the treatment of asthma.\nBy binding to this protein, Dupixent is able to inhibit the inflammatory response that plays a role in the development of atopic dermatitis.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release does not engage in disease-mongering. Instead it offers a clear description of what eczema is and what causes the condition.", "answer": 1}, {"article": "In some of the test groups, overall success rates were fairly low, Lerman noted, but the study was conducted during the Great Recession, a time when financial stress may have depressed the chances of succeeding for everyone, regardless of which approach was used.\nAbout 70 percent of smokers give up the daunting effort during the first week of trying.\nThe patch, worn on the skin, delivers a steady flow of the drug, she said.\nThe metabolite is found in blood and saliva.\nThis may seem like common sense, but no one had ever tested it before, she said.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not exaggerate the dangers of smoking.", "answer": 1}, {"article": "U.S. experts familiar with the study call it interesting but say the treatment needs more study and wonder if it would catch on in the U.S.\nThey assigned 43 children to the acupuncture group, and they received five treatments a week.\nAn improvement of two lines or more occurred in nearly 67% of those in the patching group but nearly 76% of those in the acupuncture group.\nAt 15 weeks, visual acuity with eyeglasses improved by about 1.8 lines on the vision chart in the patched eyes and 2.3 lines in those who had acupuncture.\nWhile some previous research has found acupuncture for lazy eye effective, the researchers couldn't find a study that directly compared acupuncture with conventional treatments such as patching.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering here.", "answer": 1}, {"article": "DANVILLE, Calif., April 11, 2018 /PRNewswire/ -- Palo Alto Health Sciences, Inc. (PAHS), developer of the drug-free Freespira\u00ae treatment for panic attacks and other symptoms of panic disorder, today announced that another study has demonstrated clinically significant symptom improvement, with 80% of patients panic attack free one year after treatment.\nFreespira is both easy to use and effective.\nTreatment is authorized and completed under the supervision of a licensed healthcare provider.\nOnce a licensed healthcare provider authorizes the treatment and after a single training session, the patient uses Freespira at home, performing two 17-minute breathing sessions a day over a four-week period, after which the treatment is complete.\nIndividuals with panic chronically hyperventilate, even when not experiencing a panic attack.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "This method is expensive, invasive and has some risk of complications.\nThe trial was based on the results of previous research that suggested differences in the levels of specific chemicals (butyric, pentanoic and hexanoic acids, butanal, and decanal) between patients with stomach or oesophageal cancer and patients with upper gastrointestinal symptoms without cancer.\nThis study suggests that we may be able detect these differences and use a breath test to indicate which patients are likely to have cancer of the oesophagus and stomach, and which do not.\nBoth tend to be diagnosed late, because the symptoms are ambiguous, meaning the five-year survival rate for these two types of cancer is only 15%.\nAmsterdam, The Netherlands: A test that measures the levels of five chemicals in the breath has shown promising results for the detection of cancers of the oesophagus and stomach in a large patient trial presented at the European Cancer Congress 2017 [1].\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t engage in disease mongering and provides statistics on the numbers of stomach and esophageal cancers diagnosed globally each year, which matches other sources, and this puts the disease in context for readers. But when it notes that these types of cancers have a low 5-year survival rate of 15%, it would have been better to also tell readers that, while deadly, these two cancers are relatively uncommon (accounting for less than 10% of cancer diagnoses even after excluding common, nonmelanoma skin cancer) and appear to be largely preventable through improvements in diet and other living conditions.", "answer": 1}, {"article": "Drs.\nThis is a very relevant finding, as over 200,000 patients still receive whole brain radiation in the United States each year, and the majority of patients with brain metastases have a limited number (typically three or less) of brain lesions.\nHowever, the data from our study shows that clinicians can no longer simply rely on the results of traditional lab tests or scans to assess the value of care; we have to understand the total impact of cancer therapies on our patients.\"\n\"We discovered that whole brain radiation added to focused radiation in the treatment of brain metastases \u2013 in other words, cancer that travels to the brain- reduces the number of new brain tumors over time; however, patients receiving the whole brain radiation had significantly more difficulties with memory and complex thinking than patients who only had the focused radiation,\" says Dr. Asher.\nThe study, released on July 26, 2016, shows that patients with the most common form of brain tumor can be treated in an effective and substantially less toxic way by omitting a widely used portion of radiation therapy.\n", "question": "Does the news release commit disease-mongering?", "explanation": "This ruling is a close call. Although the claim in the release that the study results could apply to tens of thousands of patients with brain tumors may be a reasonable estimate, it fails to put that number in context. The study included only a select group of patients with three or fewer metastases in their brains. By failing to mention either that one out of five patients in the trial died before the first post-treatment evaluation or that many patients with brain tumors don\u2019t match the description of those in the trial, readers are given an inflated sense of the relevance of these findings.", "answer": 1}, {"article": "Actually, nitrous is making a comeback in U.S. maternity circles. It has remained a staple of childbirth in Canada, Australia, and Britain \u2014 Catherine, Duchess of Cambridge (the former Kate Middleton), who welcomed her third royal baby, Louis Arthur Charles, last month, reportedly has used it. But it basically disappeared in the United States in the 1970s. American women preferred to be numbed below the waist with epidural anesthesia, or at least that became the gold standard for pain relief.", "question": "Does the story commit disease-mongering?", "explanation": "None.", "answer": 1}, {"article": "In a statement, she said the trial would help address how the procedure, if approved by federal regulators, \u201cshould be appropriately managed to minimize complications.\u201d\n\nSome experts have speculated that the adverse effects were dose-related.\nThe high complication rate was seen in 2006 data..\n\n\u201cI would have hoped that this sort of surveillance would be a routine part of F.D.A practice,\u201d Dr. Deyo said.\nThe use of a bioengineered protein should be \u201cdiscontinued either permanently or until further information becomes available regarding how to use it safely,\u201d said Dr. Thomas A. Einhorn, chairman of orthopedic surgery at Boston University.\nWhile use of the products in such operations has since fallen, one expert said the new report should convince doctors to stop using them in anterior cervical fusions, as the procedure is known.\nAlthough doctors are free to use any product on the market for whatever purposes they choose, companies may promote them only for their federally approved uses.\n", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\nThis story does not directly address the prevalence of back pain nor the indications for treatment; but by highlighting complications seen in surgical treatments of upper spine pain, this story\u2019s overall tone is cautionary. On the other hand, the story did not mention non-surgical approaches to dealing with back pain.", "answer": 1}, {"article": "\"How bulging is the eardrum?\nBut here's the rub \u2013 diagnosing ear infections in very young children, who tend to squirm, is not easy.\nMuch of the confusion, experts say, has been caused by studies that weren't careful enough about the diagnosis.\nIf many children in prior studies didn't really have ear infections, then it's not surprising the antibiotics didn't work for them, says Dr. Jerome Klein of Boston University, who wrote an editorial that accompanies the new studies.\nBoth studies, which appear today in the New England Journal of Medicine, find these kids get over painful ear infections faster, and have less severe symptoms, if they get prompt treatment with Augmentin, an inexpensive antibiotic often used to treat respiratory infections.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease-mongering. In fact, we wish it had spent a little more time explaining whether the only reason to give a child antibiotics was because of the pain and whether the infections ever spread or seriously threatened a child\u2019s health.", "answer": 1}, {"article": "\"There is growing evidence that concussions can change the blood flow in the brain,\" said study author Robert Hamilton, PhD, co-founder of Neural Analytics in Los Angeles, Calif., and a member of the American Academy of Neurology.\n\"The potential of having an accessible technology that detects a physiological change following brain trauma is very exciting.\nThey were also given a general concussion evaluation and had their blood pressure checked.\nBut those measurements haven't been enough to accurately detect concussion.\nThis is in contrast to traditional TCD ultrasound measurements like change in cerebral blood flow reactivity which differentiated between the two 60 percent of the time, average blood flow speed which differentiated 55 percent of the time and blood flow resistance which differentiated 53 percent of the time.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t engage in disease mongering. Concussions among athletes is an increasingly recognized health risk.", "answer": 1}, {"article": "For his part, Bruno cautioned that the long-term effects of the drug need to be studied before it can be used regularly in clinical practice.\nPatients were either given the drug or an inactive placebo.\nOne expert said the drug might prove a valuable tool against depression.\n\"In addition, we have shown little or no side effects with our compound.\"\nAntidepressant effects of the drug were seen within 24 hours and lasted an average of seven days.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not commit disease mongering.", "answer": 1}, {"article": "Long-standing American Heart Association guidelines recommend a diet primarily consisting of fruits, vegetables, fish, and other whole foods, with limited amounts of sodium, sugar, saturated fats, and refined carbohydrates.\nThey answered questions about their diet and reported how many times a week they consumed servings from separate food groups.\nEuropean Heart Journal.\nAccording to Stewart, the meaning behind the numbers is clear.\n2016.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}]